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INTRODUCTION 
There are many non-elucidated questions concerning cancer, especially of the 
breast, in which hormones are involved. The scope of this particular study 
is to bring more clarity on the role of the progestin megestrol acetate in 
the hormonal treatment of breast cancer. 
It should be kept in mind that this is a clinical study. Biochemical details 
mentioned in Chapter I serve primarily as a background for a better 
understanding of clinical effects. 
The study was done from 1974-1983 and 5 questions have provided the frame 
for this thesis: 
l. How effective is megestrol acetate in the treatment of metastatic breast 
cancer? (Chapter II) 
2. What is the role of steroid receptors in the mechanism of action of 
megestrol acetate in inducing tumor regression? (Chapter III + IV) 
3. Has the effect of megestrol acetate on some endocrine parameters any 
relation to tumor regression? What is the optimal dose? (Chapter V) 
4. In what sequence of hormonal treatment should megestrol acetate be used? 
Is there a difference with regard to the age and/or menopausal state of 
the patient? (Chapter VI) 
S. Does the combination of megestrol acetate and tamoxifen have any 
additional effect on endocrine events; especially can megestrol 
acetate-induced hyperprolactinaemia be suppressed by the administration 
of tamoxifen? (Chapter VII) 
These questions are considered in the general discussion and summary. 
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CHAPTER! 
HORMONAL INFLUENCES ON BREAST CANCER, PROGESTERONE AND PROGESTINS 
l. HISTORICAL OVERVIEW OF HORMONAL THERAPY 
The first indication that regression of advanced breast cancer can be 
induced by endocrine manipulation was the beneficial effect of 
on cancer of the breast of two women. This empirical observation 
ovariectomy 
1 
of Beatson 
in 1896 was remarkable since it was made before the concept of hormones had 
been developed. Why did he ever consider ovariectomy in the management of 
inoperable breast cancer? Many years before, while writing his M.D. thesis 
on the subject of lactation, he learned from Scottish farmers "that it is 
the custom in certain countries to remove the ovaries of the cow after 
calving if it is wished to keep up the supply of milk". This fact interested 
him greatly "for it pointed to one organ holding the control over the 
secretion of another and separate organ". Furthermore, he believed that 
·there was a similarity between lactation and mammary cancer, since common to 
both conditions was the "proliferation of generations of epithelial cells 
which block the duct and fill the acini of the gland. In lactation the cells 
undergo fatty degeneration and form milk, while in carcinoma they penetrate 
and invade the surrounding tissues 11 • 
At the same time Schinzinger2 ( 1889) in Germany suggested ovariectomy in 
premenopausal advanced breast cancer, which would cause mammary gland 
atrophy with the opportunity that the tumor would get encapsulated in the 
shrinking tissue of the gland. 
Only decades later, ovariectomy became widely used. In large series of 99 
patients Clarke3 (1905) described remissions in about 30% of the patients. 
The beneficial action of ovariectomy was not understood until steroid 
homones had been isolated forty years later. Since the availability of I I 
estrogens, androgens, progesterone, corticosteroids and ACTH after the 
1940's, endocrine therapy has played an important role 
of metastatic breast cancer and to prolong survival of 
to control the growth 
' 3-18 patlents. 
Experimental animal models appeared to be necessary to study tumor growth 
and its behaviour. Most of the early laboratory investigations of cancer of 
the breast were carried out in mouse strains with spontaneous mammary tumors 
and metastatic spread. 
Early experiments by 19 Lacassagne (1932) showed that mammary tumors in 
susceptible mice strains could be induced with large doses of estrogen. 
Foulds 20 (1949) described spontaneous pregnancy-dependent mammary tumors in 
mice, which - when they first appeared - tended to regress in pregnancies. 
Also the influence of pituitary hormones in the etiology was considered 
(Muhlbock 1956). 21 
There are serious disadvantages in the mouse tumor, they arise slowly and in 
most strains the mammary cancer of mice are hormone-independent when the 
tumors reach a palpable size. 21 Studies of the rat altered the course of 
research on breast cancer. This species has a remarkable propensity to 
develop mammary carcinoma after exposure to potent carcinogens and a 
hormone-dependent mammary adeno-carcinoma develops selectively, rapidly and 
invariably after exposure to 3-methylcholanthrene 22 (3-MC) and 7,12-
23 dimethyl-benzanthracene (7,12-DMBA). This was a very important display 
and soon almost absolute control over mammary cancer of the rat, its 
induction, prevention and cure was achieved. Rats, mice, rabbits and dogs 
are the only experimental animals in which spontaneous mammary tumors have 
been found. They have never been observed in hamsters, guinea pigs or 
monkeys .. However, spontaneous mammary carcinoma is extremely rare in rats 
while induced mammary tumors are growing locally without metastatic spread 
and thereby differ from the human tumors. 
Tumor cell studies seemed a more direct approach. It is only within the past 
years that an estrogen-responsive in vitro cell system has been described. 
Following the initial description of the MCF-7 human breast cancer cell 
' 24 25 l1ne , Brooks et al. ( 1973) demonstrated that these cells showed a 
12 variety of growth responses to physiologically relevant concentrations of 
estrogen. The studying of hormonal dependency of human breast cancer in 
tissue culture has been started. 
As mentioned, several observations suggest that estrogen plays a role in 
maintaining the growth of established breast cancer: a significant 
regression may occur after ovariectomy in premenopausal women and an 
exacerbation of growth occurred when physiological doses of estrogen were 
given to women whose tumor underwent regression following castration. 8 ,Z 6 , 27 
The concept of estrogen dependency, although not strictly proven, offers a 
working hypothesis that the diminished circulating levels of estrogens as a 
result of ovariectomy, adrenalectomy and hypophysectomy, as well as by 
pharmacological dosages of androgens and progestins, could induce a 
regression of tumors. 
On the other hand, this is unable to explain satisfactorily the tumor 
regression, which follows administration of estrogen to postmenopausal 
8 28 
women. ' 
Two different types of endocrine therapy have been applied: 
l) Ablation of endocrine glands by surgery or by irradiation. 
2) Addition of pharmacological dosages of hormones: androgens, estrogens, 
progestins, corticosteroids. 
Grossly, 30% of all human mammary cancers showed a significant regression 
following anyone of these treatments. 
With the introduction of ovariectomy for premenopausal, adrenalectomy or 
hypophysectomy for the treatment of postmenopausal patients, hormone 
deprivation through endocrine ablation became a common therapy for advanced 
breast cancer. Since only one-third of human breast cancers are 
hormone-dependent and responsive to endocrine manipulation, there was a need 
to distinguish those hormone-dependent cancer patients before great ablative 
surgery was to be performed. 
Observations, that tissues of estrogen responsive reproductive organs of 
laboratory animals contain characteristic estrogen-binding components, 
indicated by their striking uptake and retention of tritiated hexestrol or 
estradiol given 
determination as 
in vivo, led to the rationale of estrogen receptor 
. . . 29,30 Aft h . a tool for estrogen sensH1v1ty. er tee n1ques 13 
14 
were devised for the study of estrogen-receptor interaction in vitro 31 , it 
became possible also to examine tumors and to demonstrate specific 
estrogen-binding by hormone-dependent rat mammary tumors. For clinical use a 
new area of important research on steroid receptors and their significance 
in human hormone-dependent cancer, particularly in relation to prognosis and 
treatment, was opened. 
While the additive therapy with androgens and estrogens have several 
disadvantages, mainly due to unwanted side-effects, more attention was given 
during the 
47 
estrogens 
last two decades to 
. 32-44 
and progest1ns. 
the apparently less disturbing anti-
Our own interest was directed to the progestins. Although progesterone was 
discovered (under the term progestin) a long time ago4 ' 48 its clinical use 
was limited by short bioavailability. This problem has been overcome by the 
production of synthetic steroids, which are not only much more active than 
progesterone but which, unlike progesterone, are also active after oral 
administration. 
Since Huggins 32 (1962) reported that DMBA-induced rat mammary tumors could 
be 11 extinguished11 by a combination of progestin and estradiol, various 
progestins have been used in the treatment of advanced breast 33 cancer. 
After the synthesis of medroxyprogesterone acetate (MPA) in 1958 by Babcock 
34 35 . 
et al. and Sala et al. 1ndependently, it has been widely used in the 
. 36-41 treatment of metastat1c breast cancer, Megestrol acetate (MA), a drug 
which is very close to MPA, was first described by Pagani42 (1961), and is 
. 43-46 
also w1dely used. 
In summary 
Many endocrine manipulations, ablative and additive, have proven to 
beneficially influence breast cancer in a palliative way and have been 
therefore used in metastatic breast cancer. Progestins provide an endocrine 
modality which is little harmful to the patient and is easily applicable. 
2. THE PHYSIOLOGICAL ACTION OF PROGESTERONE AND THE PHARMACOLOGICAL 
EFFECTS OF PROGESTINS, METABOLISM AND EXCRETION, PLASMA LEVELS 
In the early thirties, 48 Corner and Allen (192 9) isola ted a crystalline 
substance from corpora lutea which had two important properties: it produced 
progestational proliferation in the rabbits' uterus and it could maintain 
pregnancy 
few years 
in castrated female 
49 later Butenand t 
rabbits. They named this extract progestin. A 
(1934) determined the structural formula and 
synthesized the compound. It was a steroid with a prominent ketone group and 
was therefore named progesterone. 
Since then many similar compounds were synthesized. The Advisory Committee 
on the Nomenclature of Endocrine Principles of the Council on Pharmacy and 
Chemistry of the American Medical Association has named the hormone 
50 progesterone and to its related compounds with a similar action the 
generic name progestins was given. 
Progesterone 
Progesterone is produced and secreted by the ovary, the placenta in female 
51-55 
and by the adrenal cortex in both sexes. In spite of the large amounts 
of progesterone produced, the concentration of progesterone detected in 
blood is low, The rapid disappearance of progesterone from the plasma 
appears to be due to a rapid diffusion. It is taken up by peripheral 
tissues, especially those with high lipid content, and it is transformed by 
them into numerous metabolites; but the most important site of degradation 
is in the liver. Some progesterone and its metabolites are excreted into the 
bile and later reabsorbed (entero-hepatic circulation). The plasma level in 
premenopausal women varies during the menstrual cycle; it is low in the 
follicular (0,44 - 4,8 nmol/1) and high in the luteal phase of the cycle 
(16-62 nmol/1). In postmenopausal women and men the level is very low (0,50 
- 1,25 nmol/1). 
The major degradation products are pregnanediol, pregnanedione and 
pregnanolone. After the administration of radioactive progesterone to 
humans, 40-70% of the dose may be recovered from urine and 13-20% from 
faeces within the first four days, although smaller amounts of radioactivity 15 
16 
continue to be excreted for a longer period of time. 
Progesterone is metabolised along several routes, Along one of them 
progesterone serves as a precursor for corticosteroids and androgens, and 
via androgens for estrogens (Table 1). 
Most of the physiological actions of progesterone require estrogen priming. 
Estrogens have mainly growth stimulating effects, while the action of 
progesterone is more directed towards modification and differentiation. 
However, some stimulation of growth must be present before progesterone can 
be effective (vagina, uterus, mammary gland). Exceptions include influences 
on water and electrolyte metabolism involving interaction with aldosterone 
receptors, some effects on protein metabolism and possibly its action on the 
hypothalamus affecting body temperature and appetite (Table 2). 
Practically all processes of female reproduction are regulated by 
progesterone and estrogens acting together. It is important to know that 
progesterone estrogen synergism occurs only when the ratio of estrogen to 
progesterone and the time-sequence of their interaction is optimal. 
Progestins 
It is difficult to define synthetic progestins concisely in terms of their 
respective physiological and pharmacological effects, since virtually none 
55 56 
of the effects is exclusive to progesterone. ' The synthetic progestins 
are derived from 17 a-hydroxy-progesterone, testosterone, or 19-nor-testos-
terone (Table 3 and Table 4). The 19-nor-testosterone derivates are 
distinguished by an alkyl group at carbon atom 17. This alkyl group prevents 
rapid metabolism in the liver and is essential for strong oral activity. The 
alkyl or halogen substitution of carbon atom 6 have a similar function in 
the case of hydroxyprogesterone derivates. 
The term progestin is in fact no more than a convenient partial description, 
since there are some progestins which, at least on the basis of their 
properties and effects in many animal species, could as easily be classified 
as androgens or estrogens as well. 
The alkylated and halogenated acetoxyprogesterone derivates are 
distinguished by the absence of androgenic and 
anti-androgenic and certain glucocorticoid-like 
estrogenic effect; 
57 58 
effects. ' 
they have 
Table 1. Some metabolic pathways of the most important steroid hormones. 
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Table 2 SOME SPECIFIC ACTIVITIES OF PROGESTERONE 
0 r g a n 
Endometrium 
Myometrium 
Cervical mucus 
Vagina 
Pregnancy 
Mammary gland 
Pituitary/hypothalamic system 
Sperm capacitation 
Influence of progesterone 
Transformation, growth of the uterine glands, induction of 
decidual reaction under certain conditions 
Reduced contractility 
Increase in consistence, amount reduced 
Lowering of the karyopyknotic index 
Maintenance of pregnancy 
Stimulation of tubule-alveolar growth in most mammals 
(synergism with estrogens and prolactin) 
Inhibition of gonadotropin secretion 
Inhibition 
Metabolism of sperm in the uterus Lowering effect 
Egg transport 
Tubular secretion 
Libido 
Body temperature 
Appetite 
Aldosterone 
Behaviour 
Table 3 
Progestational 
Estrogenic 
Androgenic 
Anti-androgenic 
Anti-gonadotropic 
Glucocorticoid-like activity 
55 (Adapted from Neumann ) 
Inconsistent effect (species differences) 
Decrease 
Decrease in most species 
Increase 
Increase 
Competition for aldosterone receptors, natriuresis 
Maintenance of maternal behaviour in mammals through 
interaction with other hormones 
SOME ACTIVITIES OF PROGESTINS 
Transformation of the endometrium 
Positive Allen-Doissy assay (cornification of vaginal 
smear 
Stimulation of prostate and seminal vesicle growth in 
castrate rodents (virilisation of female fetuses) 
Inhibition of androgen-induced growth of prostate and 
seminal vesicle in castrate rodents (feminisation of male 
fetuses) 
Inhibition of ovulation 
Inhibition of ACTH secretion and adrenal atrophy 
TABLE 4. ACTIVITY SPECTRUM OF PROGESTERONE AND SOME PROGESTINS 
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Metabolism and excretion of megestrol acetate 
Introduction of a 17 a-acetoxy group, a 6 a-methyl group and a double bond 
at C-6 in the progesterone molecule progressively 
metabolism of the steroid in vitro by rat and rabbit 
When megestrol acetate was given orally to rabbits 60 
reduced the rate of 
1 . 59 iver preparat1ons. 
3 
as (1,2- H2 )megestrol 
acetate the recovery of tritium in urine and faeces during the first seven 
14 days was 40.9%; administered as (6-methyl- C)megestrol acetate, 70.4% of 
the administered isotope was recovered in the same period. In the urine 
20-30% of the administered dose was in the conjugated form and 10-13% in the 
free form; faecal excretion accounted for 8-15% of the dose. Several urinary 
metabolites retained the 17 a-acetoxy-20-one and 4,6-dien-3-one structure 
present in the administered compound, two major metabolites, probably 
conjugated as glucuronide, are the 17 a-acetoxy-2 a-hydroxy-6-hydroxymethyl-
pregna-4,6-diene-3,20-dione and 17 a-acetoxy-6-hydroxymethylpregna-4,6-
diene-3,20-dione. 
14 61 Of (6-methyl- C) megestrol acetate (4-90 mg) administered to women a mean 
recovery of + 70% in the urine and + 20% in the faeces was obtained within 
seven days. Three major metabolites excreted as glucuronide conjugates have 
been found as well as free steroids. Some loss by respiration but also 
temporary storage in body fat may account for + 10% not found in the 
excrets. The biological half-life time of doses 60-90 mg was 31 days. 
Plasma level 
Several methods have been used for the estimation of plasma levels of MA, 
such as mass fragmentography and radioimmunoassay (RIA). For details see 
62-66 Adlercreutz. These methods are not strictly comparable. 
After a single oral administration of 60 mg of MA to healthy females, the 
plasma level reached a mean maximum of 43 ng/ml (21. 7 - 87.7 ng/ml) after 
1-4 hours; after 24 
7 days in the range 
hours MA was still 
66 
of 0,7-3 ng/ml. 
detectable (9.6 - 26 ng/ml) and after 
Plasma levels are greatly dependent not only on the method used, but also on 
intestinal and hepatic inactivation of the drug which again may be secondary 
to intestinal tract motility and intestinal bacteria, or administration of 
20 antibiotics, body weight, diet, liver function. 
65 Adlercreutz et al. d . l 67 . . d an Mart1n et a . 1nvest1gate the excretion of 
steroid hormones. They found that both endogenous and exogenous natural and 
synthetic estrogens and progestins are excreted to a significant degree in 
bile and are partly reabsorbed from the intestine. One of the most important 
consequences of this enterohepatic circulation is their delaying effect on 
the final elimination of steroids from the body. In addition, the products 
of intestinal metabolism may be biologically more active than those excreted 
via the bile. 
Orally administrated progesterone has little biological effect. It has been 
65 67 
suggested ' that the 17-acetoxy group in MA and MPA hinders the removal 
of the side-chain by intestinal bacteria. 
The double bond at C6 of MA is very resistant to reduction by intestinal 
bacterial enzymes. MA is relatively unaffected under incubation conditions 
of human mixed intestinal flora. 
In summary 
Progesterone was discovered in 1930, but its use in the treatment of 
metastatic breast cancer besides other ablative and additive hormonal 
treatment was limited by short bioavailability. This has been overcome by 
the production of synthetic progestins in sixties, which are more active 
than progesterone and, unlike this, are also active after oral 
administration. 
Most of the known actions of progesterone require estrogen priming. Estrogen 
has mainly growth stimulating effects, while the action of progesterone is 
more directed towards modification and differentiation. 
Synthetic progestins may, on the basis of their chemical structure, have not 
only progestational but also androgenic, anti-androgenic and glucocorticoid 
properties. 
The plasma level after a single oral administration of megestrol acetate (60 
mg) reached the maximum after 1-4 hours; was still detectable after 24 hours 
while a mean recovery of ±. 70% in the urine and + 20% in the faeces was 
obtained within 7 days. The biological half time of this dose was 3-l- days. 
21 
3. MECHANISM OF ACTION OF HORMONES ON BREAST CANCER 
General remarks 
The growth, development and function of the human mammary gland is dependent 
on a number of hormones, among which estrogen and prolactin exert the most 
promoting effects. It may be expected that some tumors arising by malignant 
transformation of mammary gland cells would retain at least partly the 
sensitivity to these hormonal controls. Striking observations in this 
respect are that hormone-dependent mammary tumors regress not only after the 
host is deprived from estradiol, but also after an excess of estradiol is 
given. 8 >32 This suggests that an equilibrium in the turnover of the cell 
population can be altered by hormonal treatment and that cell destruction 
may prevail over cell multiplication. 
McGuire 68 (197 5) postulated the following hypothesis: normal mammary cells 
contain cytoplasmic or membrane receptor sites for each of the hormones 
known to influence the growth and function of the mammary gland. These 
receptor sites are responsible for the initial interaction between the 
hormone and the cell, and function to trigger the biochemical chain of 
events characteristic for the particular hormone. When malignant trans-
formation occurs, the cell may retain all or only part of the normal 
population of receptor sites. If the cell retains the receptor sites, its 
growth and function are potentially influenced by changes in the hormonal 
environment as in a normal cell. However, if the receptors are lost from the 
cell as a consequence of malignant transformation, the cell is no longer 
recognized as a target cell by circulating hormones and endocrine control is 
absent. 
The presence of specific receptors in mammary tumor tissue may therefore 
indicate hormonal dependency, thus aiding to select breast cancer patients 
who will actually benefit from endocrine therapy. 
Although a positive estrogen receptor (ER) assay is found in 70-85% of the 
68 breast tumors, only 55-60% of these respond to endocrine therapy. Not all 
receptors are present in each individual cell. There is now good evidence 
that ER assay offers also a valuable indicator of prognosis. Especially in 
22 those patients found to have axillary node me1:astases at operation, it has 
69 70 . been found that ER+ tumors recur more slowly than ER- tumors ' wh1le 
these patients have a longer survival. 71 This finding may be associated 
with the observation that ER+ tumors tend to be highly differentiated72 , 73 
with slower growth74 and a lower thymidine labelling index75 and thus being 
less aggressive than ER- tumors. 
±_ Thirty per cent of ER+ tumors fail to show a significant degree of 
regression after endocrine manipulation while ±_ 10% ER- do respond. Factors 
responsible for this discrepancy may be variations in assay technique, 
different cut-off levels used to distinguish between ER+ and ER-, and the 
degree of cellularity of the tumor specimen. 76 
The cytoplasmic ER assay is not necessarily a measure of functional activity 
of estrogen receptor in the cell. The estrogen molecule combines with the 
receptor protein in the cytoplasma but the complex needs to be translocated 
to the nucleus before it can stimulate RNA synthesis. Possibly the ER 
complex could be defective and fail to translocate to the nucleus or to 
stimulate RNA and protein synthesis. 
The progesterone receptor (PgR) appears to be dependent on estrogen 
stimulation. Its presence has even been suggested as a marker of a 
functional estrogen receptor. PgR has been reported in 83% of breast cancer 
specimens containing more than 100 fmol ER/mg cytosol protein. 77 
Based on present knowledge a generalised theory of steroid hormone action 
has been developed. In tissues, responsive to both estrogens and 
progesterone, estradiol associates with a specific estrogen receptor which, 
after a temperature-dependent modification, enters the nucleus, associates 
with the nuclear chromatin, and induces production of RNA, further 
production of estrogen receptor and formation of specific progesterone 
receptor. The latter, in turn, facilitates the action of progesterone on the 
nuclear chromatin. 
As both androgens and glucocorticoids have therapeutic effects in breast 
cancer, receptors for these steroids have been sought and also found. 
Estrogen, progesterone, androgen (AR) and glucocorticoid (GR) receptors were 
found in the human breast cancer line MCF-7, 78 and in DMBA-induced rat 
31,79 83 84 23 
mammary tumors. ' Allegra et al. studied the occurrence of ER, PgR, 
AR and GR in a large series of patients with primary and metastatic breast 
cancer. The presence of ER, but not that of PgR, AR and GR, showed a 
relation to menopausal status. In premenopausal patients, the mean ER 
quantity of the tumors is lower than in postmenopausal patients; to explain 
this it has been suggested that in the former group free ER sites are 
occupied by endogenous estrogen and are therefore unavailable to the assay. 
Another explanation is that of Saez et al. 85 suggesting that it is the 
cyclic progesterone secretion which inhibits estrogen stimulation of new ER 
synthesis in premenopausal women. 
Although the role of prolactin is still 
that some transplantable mammary cancers 
uncertain, it has become apparent 
86 87 88-90 
of the rat ' and man also 
bind polypeptide hormones, in particular prolactin. Pearson et a1. 91 found 
prolactin receptors in 51% of human breast cancers in both estrogen positive 
and negative tumors. 
Hormone-induced tumor regression 
may result in changes in one or more of cell kinetic functions such as 
prolongation of the cell cycle, decrease in the fraction of cells in cycle 
or increase in the rate of cell loss. 
If a tumor is of a well-differentiated type, only a small proportion of the 
cells are clonogenic and if they leave the cycle by giving rise to mature 
cells, the tumor will regress. In the case of an initially multiclonal 
tumor, loss of hormonal control could occur by clonal selection. 92 The 
resistant clones will proliferate when the sensitive ones have been 
eradicated by the endocrine therapy. Endocrine therapy kills only a 
proportion of cells in most late cancers so that the tumor does not 
disappear, but merely reduces in size. It temporarily stabilizes at a size, 
where the number of replicating cells is more or less equal to the number of 
cells dying. At some stage during tumor progression, part of the malignant 
cell population will overcome this block imposed on their ac ti vi ty by the 
h 1 . 93 armona env1ronment. 
24 Hormonal control of breast cancer probably involves interrelationships 
between the actions of a number of hormones on the same cell. Some human 
breast cancers are able to synthesize hormones, either steroid or protein in 
type. It has been reported that one and the same mammary carcinoma can 
synthesize progesterone, androgen or estrogen from cholesterol and if this 
94-97 
were so, it would have a profound bearing on the approach to therapy. 
In summary 
The growth, development and function of the human mammary gland is sensitive 
to a number of hormones. It could be expected that after malignant 
transformation some tumors would retain these hormone dependencies. A local 
hormonal action can be exerted only if specific receptors are present in the 
tumor celle The presence of an estrogen receptor seems a valuable indicator 
for the prognosis as to response to hormonal treatment. In addition, the 
presence of a progesterone receptor, which appears dependent on estrogen 
stimulation, has been suggested as marker of a functional estrogen receptor. 
The presence of other hormone receptors in breast cancer cells such as for 
androgen, glucocorticoid and prolactin, has been established. 
Hormone-induced tumor regression may be due to changes in the cell cycle 
leading to its prolongation, to a decrease in the number of cells in cycle 
or an increase in the rate of cell loss. 
25 
4. PROGESTIN-INDUCED TUMOR REGRESSION 
must be considered in relation to the complete endocrinological milieu on 
the breast cancer cell and should be correlated with effective interference 
with estrogen-regulated growth processes. Hormonal manipulation in hormone 
dependent tumors may be directed towards: 
1. Direct interference with steroid-receptor proteins 
There is very little evidence for an interaction of progestins with 
estrogen receptors in the estrogen target tissue. 
Estrogen acts through estrogen receptors to affect transcription and 
protein synthesis of a new estrogen receptor. Progestins at physiological 
concentrations act through the progesterone receptor to produce 
diminution of new estrogen receptor synthesis. This diminution of the 
cytoplasmic ER protein results in a reduced ability of estrogen to 
stimulate uterine growth. 98 Di Carlo et a1. 99 observed a similar effect 
on rat uteri using an oral dose of 8 mg/kg of medroxyprogesterone 
acetate. 
Using pharmacological concentrations of different progestins (up to 
50.000 fold in excess) an effective competition with estradiol binding 
has been reported in rats.lOO 
The presence of a progesterone receptor suggests that the action of 
progestins in breast tumor cell homeostasis involves a receptor protein. 
In fact the evidence for interaction of progestins with estrogen 
receptors is sparse, which is not the case for androgen receptors. 
Detailed studies on various androgen-target organs in mice, especially 
the kidney, have shown that progestins can exert a variety of effects 
dependent on steroid structure, dose, target organ and end-point 
d . 101,102 h h stu 1es. T ese parameters toget er determine whether the effects 
of the progestins are androgenic, synandrogenic or anti-androgenic. This 
can be explained by the interaction of the progestin with the androgen 
receptor. There has been established a relation of steroidal structure to 
the capacity for modulation of androgen action. A 6 a-methyl substitution 
correlated with androgenic activity, which was enhanced by a 17 a-acetoxy 
26 substitution. 58 
In addition, introduction of a 17 a-acetoxy group produces significant 
anti-glucocorticoid activity. The further presence of a 6 a-methyl group 
h d th . . . f h . 57 d h . 1 en ance 1s act1v1ty o synt et1c progestins an t e s1mi ar 
interactions of the progestins with the glucocorticoid receptor was 
103 
reported , if progestins were used in pharmacological (200-fold higher) 
concentration. 
2. Direct cytotoxic effect 
The morphological changes following therapy with progestins were observed 
on endometrial carcinoma clinically and experimentally, both in vitro and 
in vivo using methods such as histology, histochemistry, electron 
microscopy, liquid scintillation radioautography and historadio-
104 
autography. 
These findings suggest that the mechanism of action of progestins is also 
directly located within the cell. In vitro studies using short-term 
incubation systems suggest that the inhibition of DNA and RNA synthesis 
as effect of progesterone and progestins in endometrial carcinoma is dose 
. 105 106 107 dependent both ln humans ' and rodents. Dose dependent was also 
the inhibition of 3H-thymidine incorporation into DNA and the mitotic 
activity of experimental mammary tumor cell line MCF-7, incubated with 
MPA. 108 
High doses of progestins produce tissue necrosis, but at low concen-
trations tissue differentiation. Regression in endometrial carcinoma is 
attributed to growth suppression and degeneration. These alterations are 
accompanied by a decrease and eventual arrest in mitotic activity with a 
drop of the mitotic index, increase in shrinkage necrosis (apoptosis) and 
cell digestion (autophagy). 105 
3. Influence on several endocrine events 
One of the most important effects of progestins is the lowering of LH/FSH 
secretion with subsequent decrease of circulating estrogens and 
51 55 109 
androgens 8 ' ' 27 
Their anti-androgenic effect is the result of lowered plasma testosterone 
levels and in addition an increasing rate of catabolism of androgens due 
110 
to increased hepatic 5 a-reductase activity resulting in a further 
lowering of plasma testosterone levels. This also leads to a lower rate 
of androgen conversion to estrogens and consequently to lower target 
tissue uptake of testosterone. The decrease of the SHBG concentration in 
the plasma may be attributed to these anti-androgenic properties 
111,112 
too. 
The relation between the steroidal structure of progestins and the 
capacity for modulation of androgenic action has been determined. 58 
A 6 a-methyl substitution was correlated with androgenic activity and was 
enhanced by a 17 a-acetoxy substitution. Besides competing with estrogen 
for specific estrogen receptors, progestins produce their anti-estrogenic 
effect by blocking the secretion of gonadotropins as mentioned above and 
by accelerating the enzymatic transformation of estradiol into 
113 
estrone • Thus the length and degree of cell exposure to the most 
effective estrogen will be reduced. 
A glucocorticoid-like effect has been found in animal experiments. 
114 Salander reported adrenocortical atrophy after exposure to high doses 
of megestrol acetate (2 mg/rat/day). Orally administered progesterone is 
devoid of glucocorticoid activity, but the introduction of a 17 a-acetoxy 
group produces significant glucocorticoid activity. The additional 
presence of a 6 a-methyl group provides significant eosinopenic and 
hyperglycaemic properties, however, a 6 a-methyl in combination with 
6-ene reduced these by about 50%. Megestrol acetate has a weak gluco-
corticoid activity, while medroxyprogesterone acetate has a stronger one, 
because of absence of this 6-ene binding. These glucocorticoid actions of 
progestins may be mediated by the compounds themselves, or by their 
b 1 . 57 meta o 1.tesa In addition, competition for glucocorticoid receptor 
binding has been . 103 ment1oned. 
There are only few data about the influence of insulin on tumor growth. 
During progestin therapy hyperinsulinaemia may be induced. The effect of 
insulin on tumor growth or regression should therefore be considered~ 
28 Insulin is a critical hormone in the normal differentiation of the 
mammary gland and is required for normal lactogenesis in rodents. 
Although an important regulatory role for insulin in human breast cancer 
has not been established, in vivo it has been reported that in tissue 
cultures at "physiologic" concentration insulin strongly stimulates the 
115 growth of both human and DMBA-induced rat mammary cancer cell 
lines. 116 In long-term tissue culture of human mammary cancer cell lines 
specific receptors for insulin 
binding and its biological effect 
In summary 
have been demonstrated 
117 
are well correlated. 
and specific 
Progestin-induced tumor regression must be considered in relation to the 
complete endocrinological milieu on the breast cancer cell and should be 
correlated with effective interference with an estrogen-regulated growth 
process. Hormonal manipulation in hormone dependent tumors may be directed 
towards: 
1. Interference with: 
- estrogen-receptor interaction, synthesis and turnover of estrogen 
receptor; 
- other receptor proteins than those for estrogen. 
2. Cytotoxicity: large concentrations of progestin could have a damaging 
effect on cellular organelles. 
3. Influence on several endocrine events such as decrease of concentration 
of LH,FSH,estrogens,androgens,cortisol and ACTH. 
29 
5. EFFECTS OF PROGESTINS ON CARBOHYDRATE METABOLISM AND INSULIN, LIPID-, 
PROTEIN-, WATER- AND SALT METABOLISM 
Effect on carbohydrate metabolism and insulin 
Because of the well-known adverse effects of pregnancy on the 
metabolic equilibrium in diabetic women, Beck118 (1969) undertook a study on 
the pancreatic response to glucose in rhesus monkeys treated with i.m. 
progesterone. No consistent effects on either the mean fasting serum glucose 
or insulin concentrations were found but progesterone treatment caused a 
marked increase in the plasma insulin response to intravenously administered 
glucose, while the disappearance rate of glucose remained constant. At the 
same time progesterone reduced the sensitivity of these animals to exogenous 
insulin. Progesterone administration also induced pancreatic islet hyper-
119 trophy and exaggerated insulin secretion in vitro in response to glucose. 
The existence of sex steroid receptors in pancreatic islets has been 
120 
reported. Moreover, in vitro cultures of islets with progesterone showed 
an increased insulin secretion, suggesting a direct ~-cytotropic action of 
121 
this hormone. 
The liver is a major organ for steroid metabolism, so effects of progester-
one on hepatic metabolic pathways could be expected. Progesterone adminis-
tration to the intact female rat increases the glycogen content of the liver 
1 . 122 and suppresses hepatic g uconeogenesls. 
Progesterone also blunts the hyperglycemic effects of cortisol adminis-
tration118 and lowers the plasma glucose response to intravenous arginine 
. f . 123 1n USlOll. 
Since all of these effects are insulin-like and since progesterone induces 
hyperinsulinaemia, one cannot distinguish between direct effects of pro-
gesterone on these processes and indirect actions mediated by augmented 
. l" . 124 1nsu 1n secret1on. 
On the other hand progesterone administration to rats reduces the 
sensitivity of adipocytes and skeletal muscle to insulin-induced glucose 
30 uptake and oxidation. 125 • 126 
Effect on lipid metabolism 
In the female rat exposed to progesterone, hyperphagia and weight gain 
developed with substantial increases in carcass fat. 127 
Progestins 
128 
number .. 
enlarged the adipose cell size but did not affect the cell 
Progesterone also induces increased lipoprotein lipase activity 
129 in the liver and mammary gland. Administration of progesterone to humans 
and animals has little effect on plasma-free fatty acids or triglycerides. 
Effect on protein metabolism 
130 After protein-anabolic effects in animals have been reported , only few 
reports on protein metabolism in have been reported in literature. 
Pregnancy as well as administration of estrogens or combined oral 
contraceptive agents are associated with significant alterations of plasma 
proteins. 131 There is little evidence, however, that progesterone has major 
131 132 
effects on these. ' 
133 The work of Landau and Poulous (1971) suggests that progesterone has a 
weak catabolic action in man. The basic effects are a lowering of several 
plasma aminoacids and an increased total urinary nitrogen excretion without 
associated aminoaciduria. They concluded that loss of protein from muscle 
may not be pronounced, since the increased urinary nitrogen was largely 
urea. 
There are no reports on the effects of progestins. 
Effect on water and salt metabolism 
The natriuretic effect of progesterone in humans was reported by Landau et 
a1. 134 (1965) and has further been confirmed in animals. It is likely that 
this hormone participates in the physiological control of water and salt 
metabolism, especially when its secretion rate is high, as in the second 
phase of the menstrual cycle and during pregnancy. A study of the binding of 
progesterone and some of its metabolites to the mineralocorticoid 
displace 3H-aldosterone 135 receptor revealed that progesterone was able to 
from its binding sites. 
Only a few studies have been 
and salt metabolism during 
carried out concerning the alteration of water 
136 progestin treatment. The progestins were 31 
32 
shown to have a much lower natriuretic effect than progesterone itself. 
In summary 
Progesterone induces hyperinsulinaemia, promotes glycogen storage in the 
liver, stimulates deposition of body fat, increases natriuresis and might 
have a weak catabolic effect. 
With progestins an additional effect on gluconeogenesis should also be 
considered because of glucocorticorticoid properties of some progestins, 
while the natriuretic effect seems to be lower. 
6. RELATION OF PROGESTERONE AND PROGESTINS TO PROLACTIN 
Prolactin is important for the development and growth of mammary tumors in 
mice and rats 137 and is also a hormone of primary importance that influences 
the growth of hyperplastic nodules and their conversion to tumors in mice. 
In contrast, once mammary tumors have developed, prolactin does not appear 
138 to be necessary for their maintenance or growth. 
In contrast to the murine mammary tumor model, in DMBA-induced mammary 
tumors in rat, the growth continues to be influenced by the hormonal 
environment, once 
139 
tumor growth. 
tumors are induced. Increases in serum prolactin enhance 
of prolactin on tumor growth in The stimulatory effect 
140 
rats requires the presence of estrogen~ 
In human breast cancer the role of prolactin is much less clear. The 
inability to demonstrate elevated prolactin levels in patients with breast 
cancer, however, does not preclude the possible importance of prolactin in 
the pathogenesis of breast cancer or the possible usefulness of its 
suppression in therapy. 141- 144 However, some data seem to point to elevated 
levels in patients with malignant and benign breast serum prolactin 
lesionsl45-147 relatives and daughters of patients 
luteal phase 148 , 149 although recently during the 
with breast cancer 
published data 150 
concluded that the "early evening prolactin peak11 cannot be used easily to 
identify individual risk in 1st degree relatives of breast cancer. 
There is some evidence that seems to contradict a major role of prolactin in 
151 . breast neoplasms. McMahon et al. (1973) argumented that prolact1n levels 
are very high during pregnancy and lactation and yet these two conditions do 
not increase the risk of breast cancer (unless the first pregnancy is after 
age 35). Possibly the interaction between steroid and polypeptide hormones 
during these periods is such that these high levels of pro lac tin lead to 
glandular differentiation rather than to growth promotion and the role of 
prolactin may enhance a mutagenic effect of estrogen rather than to be a 
. . lf 152 prlmary mutagen ltse • 
Binding of prolactin to specific receptors located on the membrane of the 
cell is the first event in the action of this and other polypeptide 33 
34 
hormones. Specific prolactin binding has been identified in a number of 
tissues of experimental animals and humans including the chorioid plexus of 
the brain, liver, kidney, mammary gland, adrenal, ovary, testis, prostate, 
. 1 . 1 d 15 3-15 7 sem1na ves1c e an uterus. 
Prolactin binding capacity in human mammary carcinoma is low compared with 
h f d . 1 . . . 1 . 155 t at oun 1.n pro actJ..n-responsJ..ve exper1menta mammary carc1noma. 
The role of progesterone in prolactin release or inhibition has not been 
158 
elucidated. Haug (1979) studied the effects of progesterone, 
testosterone, corticosterone and TRH on estrogen-induced prolactin synthesis 
and cycoplasmic estrogen receptor levels in a clonal strain of rat pituitary 
tumor cells. His data strongly suggest that progesterone inhibits 
estrogen-induced prolactin synthesis by decreasing the number of available 
estrogen receptor sites. 
159 Administration of MFA or MA to rats bearing DMBA-induced mammary tumors 
or estrogen-induced prolactinomas 160 caused a decrease in the circulating 
prolactin levels. 
On the other hand, progesterone administered i .m. induced an acute release 
f 1 . . . d . . d 161 o pro act1n 1n estrogen-pr1.me ovar1ectom1ze women. In one subject 
given progesterone prior to ethinyl-estradiol priming, no effect on the 
circulating levels of prolactin was observed. They suggested that this 
effect of progesterone may be mediated through a reduction of hypothalamic 
dopamine, the prolactin inhibiting factor. Estrogen promotes dopamine 
turnover, progesterone on the other hand, may reduce dopamine activity by 
virtue of its ability to inhibit tyrosine hydroxylase (the rate-limiting 
enzyme for catecholamine synthesis) as has been demonstrated in the median 
eminence of ovariectomized rats after estrogen priming, 162 • 163 
In addition, progesterone and several of its A-ring saturated metabolites 
are potent inhibitors of the NADPH-dependent microsomal drug metabolizing 
164 
system. Tyrosine hydroxylase, appears to be likewise susceptible to 
inhibition by progestins. Hyperprolactinemia was reported in women receiving 
low dose of medroxyprogesterone acetate for contraception. 165 On the other 
hand during treatment of metastatic breast cancer with high dosages no 
166 
significant changes were found. 
Prolactin could be involved in the development and growth of breast tumors, 
at least in a supportive role not only in animal models 167 but also in 
h 137,168 umans .. 
Recently reports were published about the prophylaxis of spontaneous mammary 
tumorigenesis in rats by inhibition of prolactin secretion using the 
prolactin suppressor bromocriptine 169 and in DMBA-induced tumors in rats and 
. 170 
mlce .. 
Welsch et a1.
171 (1982) used the antiestrogen tamoxifen as prolactin 
suppressor and they found the same reduction of incidence of mammary cancer 
in DMBA-treated female rats as using bromocriptine, while a further 
reduction occurred with the combination of both. 
Even though data about the involvement of prolactin in malignant breast 
tumor growth in humans are conflicting, the detection of prolactin receptors 
in about 35-50% of human breast cancer with apparent lack of correlation 
with steroid hormone receptors 91 ' 172 indirectly supports an importance of 
this hormone as a growth factor in malignant neoplasia. 
Recently Dogliotti et a1. 173 (1983) reported that with a combination of the 
progestin MPA and bromocriptine in the treatment of metastatic breast cancer 
a higher response rate (C.R.+P.R. = 54%) of longer mean duration of response 
(24 months) was reached than could be expected from an unselected (to ER 
status) group of patients with metastatic breast cancer. 
In summary 
The influence of progesterone or progestins on the secretion of prolactin 
has not been elucidated. They seem to cause a release in humans, while in 
animal models (DMBA-induced mammary carcinoma or estrogen-induced 
prolactinomas in rats) they cause a decrease of the circulating prolactin 
levels. 
There is no equivocal evidence that lowering serum prolactin levels in 
itself as a primary goal is of benefit for the treatment of metastatic 
breast cancer in man. 
The influence of combination treatment of a steroid and a prolactin release 
inhibitor deserves further investigation. 35 
7. ADVERSE EFFECTS 
A major goal of cancer therapy is to find an optimal relationship between 
desired and undesired effects of a given treatment. 
The pattern of undesired effects of megestrol acetate and other progestins 
is partly similar to that observed with other steroid-hormonal agents such 
as estrogens, glucocorticoids and androgens: weight gain (however, without 
fluid retention), increase in blood pressure, changes in carbohydrate 
metabolism, blood coagulation, thromboembolic disorders, vaginal bleeding. 
Hypercalcaemia has not been reported. There are no reports about adverse 
effects of megestrol acetate concerning deterioration of glucose 
174 tolerance , although this has been reported in patients using 
175 176 
acetate. ' Weight gain is a very common medroxyprogesterone 
177 
observation. Studies of blood coagulation in women 
a contraceptive 178 showed 
treated with 
megestrol acetate implants as normal values 
without a difference between short and long-term treatment. 
Brema et a1. 179 (1981) studying several hematologic parameters during 
treatment with a high dose of medroxyprogesterone acetate found that 
prothrombin time (PTT), thromboelastogram (TEG), anti-thrombin III and 
platelet adhesiveness underwent statistically significant changes, tending 
towards hypercoagulability, although, on the average, they did not exceed 
the upper normal ranges. 
There are many data concerning the relation between thromboembolic diseases 
d l . 180 h an ora contraceptlves • However, t ere seems to be a correlation with 
their estrogen content, and factors as age, weight, cigarette smoking, 
history of hypertension or diabetes mellitus multiplied the risk of 
cardiovascular disease. 
In order to prevent and minimize possible adverse effects, careful clinical 
and laboratory assessment is important to identify before the start of 
therapy those patients, who are at high risk to develop undesired effects 
during progestin treatment. Patients with a history of hypertension, 
obesity, diabetes, myocardial infarction, thromboembolic disorders and heavy 
smokers should be carefully monitored during the treatment. 
36 With the accumulation of more knowledge on the mechanism of action of 
natural and synthetic steroids, more rationale as with regard to the optimal 
effective dose, their combination or sequence of use, will follow. 
In summary 
The pattern of undesired effects of megestrol acetate and other progestins 
is similar to that observed with other steroid hormonal agents, but without 
fluid retention. Therefore, careful clinical and laboratory assessment as to 
weight gain, blood and urine sugar and cardiovascular control is 
recommended. 
37 
8. EVALUATION OF CLINICAL RESULTS 
In the following studies the responses are assessed according to the 
generally accepted method, recommended by UICC (Union Internationale Contre 
le Cancer) 181 ; the recording of lesions was done by "dominant sites", which 
182-184 is commonly used. By this method patients are always classified into 
the visceral category when visceral lesions are present, the osseous 
category when skeletal lesions exist without visceral involvement, and into 
the soft tissue category when only sub- and cutaneous, mammary of 
superficial lymphatic structures are involved: 
I. Visceral - visceral (lung/liver) metastases 
- visceral + bone metastases 
- visceral + bone + soft tissue metastases 
II. Osseous - bone metastases 
bone + soft tissue metastases 
III. Soft tissue soft tissue metastases 
However, as Rozencweig 185 (1975) pointed out in an extensive survey article, 
the interpretation of the prognostic value of 11 dominant sites" categories, 
based the general view that the prognosis is increasingly worse in the 
order: soft, osseous and visceral tissue, is difficult due to their very 
definition of these categories and the criteria of response to treatment. 
Thus, soft tissue lesions are often the sole objective criterion of 
evaluation in patients belonging to the osseous or even visceral category. 
Other factors may be included in the evaluation of therapeutic trials, such 
as disease-free interval, number 186 of sites , type of organ and degree of 
. 184 187 lnvolvement. ' 
The categories of response are as follows: 
Complete response. Disappearance of all known disease. In the case of 
lytic bone metastases: these must be shown radiologically to have calcified. 
Partial responses 50% decrease in measurable lesions, and objective 
38 improvement in evaluable, but non-measurable lesions. No new lesions. It is 
not necessary for every lesion to have regressed to qualify for partial 
response, but no lesion should have progressed. 
No change. Lesions unchanged (i.e. < 50% decrease or < 25% increase in the 
size of measurable lesions). 
If non-measurable, but evaluable lesions represent the bulk of disease and 
these clearly do not respond, even though measurable lesions have improved, 
then this is considered as "no change" and not "objective regression". 
Progressive disease 
1. Mixed- some lesions regress while others progress or new lesion appear. 
2. Failure - progression of some or all lesions and/ or appearance of new 
lesions. No lesions regress. 
All lesions should be bidimensionally measured at each assessment and the 
sum of the product defined. When multiple lesions are present, only a 
representative number of eight may be selected for measurement. 
In summary 
The results of clinical trials should be considered with regard to 
inaccuracy of assessment. The prognosis and response may not only depend on 
the site of metastases, but also on the number of sites, size of metastases 
and degree of organ involved. 
39 
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CHAPTER II 
Progestin Therapy in Advanced Breast Cancer: 
Megestrol Acetate -An Evaluation of 160 Treated Cases 
J. ALEXIEVA-FIGUSCH, MD, H. A. VAN GILSE, MD, W. C. J. HOP, PHD, C. H. PHOA, MD, 
J. BLONK-v.o. WIJST, MD, AND R. E. TREURNIET, MD 
Progestin megestrol acetate treatment of 160 postmenopausal women with progressive metastatic breast 
cancer is evaluated. Objective remission was found in 48 patients (30%) and stabilization of disease 
occurred in 58 (36%) cases. In each of these response categories, the median time interval before 
subsequent progression took place was nine months. Patients with a postmenopausal age of more than 
five years showed a significantly higher remission rate than did younger patients. In addition, great 
differences in remission rates were apparent between groups of patients classified according to 
dominant sites and separate sites of lesions. The length of disease-free intenal did not prove to be 
of great importance in predicting the remission. No great differences in remission rates were found be-
tween patients treated with megestrol acetate as the first hormonal treatment and those previous))' 
treated with hormones. Side effects were negligible; a moderate weight increase without dem-
onstrated fluid retention was found during therapy in 10% of the cases. Toxicit)" was not encountered. 
Megesterol acetate therapy ma:y be the first choice of treatment in late postmenopausal patients with 
soft tissue and lung metastases. 
Cancer 46:2369-2372, 1980. 
M EGESTROL ACETATE (17o:-acetoxy-6-methyJ-preg-na-4,6-diene-3,20-dione) is a synthetic, highly 
potent progestin. Its metabolism in animals and man 
has been studied. 4 - 1; and it seemed to have mild 
glucocorticoid-like, antiandrogenic, and antiestrogenic 
properties. The mechanism of action is not clear. 
Since the production of new synthetic progestins in 
recent years, a great variety of these agents have 
been used in clinical practice. Due to its relative 
lack of side effects, there is an increasing tendency 
to use progestin therapy as a first choice in the 
management of postmenopausal breast cancer. 
Sto!1 1:1 has found remissions in 2 of II patients with 
an oral dosage of 30 mg of megestrol acetate. Ansfield 
et a!. 1 initially reported remissions in 7 of 30 
patients (23.3%) with metastatic breast carcinoma, who 
were treated with daily oral doses of 160 mg of 
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rnegestrol acetate. They suggested that rnegestrol 
acetate may be effective at any time in the sequence 
of therapy. including after chemotherapy. 
In a later report,~ Ansfield and co-workers verified 
the results of their previous study and often used 
megestrol acetate as the initial hormonal therapy in 
postmenopausal patienh in sequential treatment of 
disseminated disease. 
In our Institute. treatment with megestrol acetate in 
advanced mammary carcinoma was begun in 1969. The 
dosage was 60 mg. analogous to that used by Kuipers"' 
in the treatment of endometrial carcinoma. Preliminary 
results have been reported.:; 
Intending to achieve a maximal clinical response. we 
gradually increased the dose over the years to the 
present 180 mg daily. 
In this report. the statistically analyzed results of 
a retrospective evaluation of the treatment with 
megestrol acetate are presented. The emphasis is on 
identification of patients likely to respond. e.g .. 
according to age, metastatic sites. optimal dose with 
minimal side effects. length of duration of the response. 
and ranking according to other treatment modalities. 
Materials and :vtethods 
Two hundred and twenty-seven postmenopausal 
women with progressive metastatic breast cancer 55 
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FIG. 1. Percentages of patients without progres-
sion according to treatment response. A = remis-
sion: 8 = stable disease. 
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received megestrol acetate therapy between 1969 and 
1978. The effect of treatment could not be evaluated 
in 67 cases for a variety of reasons, including concur-
rent radiation therapy, surgical excisions, unmeasur-
able disease, or insufficient follow-up; 160 cases 
having measurable progressive disease at the start of 
the treatment, which means that new lesions had 
appeared or that the previously known lesions were 
increasing in size, were evaluable. These findings 
were objectively demonstrated by appropriate clinical 
and biochemical investigations (skeletal survey, bone 
and liver scans, color photographs with caliper meas-
urement, hemoglobin, erythrocytes, leukocytes and 
platelet counts, sodium, potassium, calcium, phosphorus, 
BUN, creatinine, total protein, alkaline phosphatase 
with liver and bone fractions, SGOT, SGPT, LDH). 
These investigations were repeated after six weeks 
of treatment to assess response objectively. Criteria 
for assessment of response were those of Hayward 
et at .. ~ which have been adopted by the EORTC 
Cancer Group. The review and decision on the 
quality of response for each case were made by 
agreement between two independent reviewers. 
TABLE:. 1. Response to Treatment According 
to Po~tmenopau~al Age 
Response 
remission 
stable 
progression 
Total number of patienb* 
Chi-square test: P < 0.01. 
Postmenopausal age 
<5 years 
5(9'/() 
23 
25 
53 
~s years 
41 (40')() 
33 
28 
102 
* The postmenopausal age was not clear in five patients becau~e 
of prior gynecological operations. 
18 months 
Megestrol acetate (Niagestin~" 15*) was given in 
daily oral doses varying from 60 to 180 mg in 4 equal 
fractions. The dose was gradually increased over the 
years to improve remission rates. There was no 
randomization in assigning the dosages. Follow-up in-
vestigations were carried out every six weeks or 
earlier if warranted. The drug was continued until the 
disease progressed. 
Results 
In 48 of 160 patients (30%), an objective remission 
was noted. Stabilization of disease occurred in 58 cases 
(36%). The median time-interval before progression of 
the disease was nine months in each category (Fig. 1). 
Of the 54 patients with progressive disease at six 
weeks, two patients showed signs of activation of 
the process. Classification of patients according to 
postmenopausal age showed that those with a post-
menopausal age of more than five years had achieved 
a significantly higher remission rate than did the 
younger group (Table !). 
Great differences in remission rates were observed 
among groups of patients classified according to the 
dominant site of the lesions. Table 2 shows that, 
for patients of postmenopausal age less than five 
years, the low remission rates according to dominant 
site did not greatly differ. For the elderly patients, 
significant diffe,..ences were observed (Table 2). No re-
lation could be established between remission rates and 
length of disease-free interval. For patients receiving 
megestrol acetate as the first hormonal therapy, a 
remission was noted in 14 of 59 cases (24%). When 
patients had experienced previous hormonal treatment, 
remission was found in 34 of 101 patients (34%). 
~ Niagestiw" 15 ( 15 mg tablets of megestrol acetate) was supplied 
by the Novo Research Institute. Copenhagen. Denmark. 
T.-'I.BLL 2. Re~ponse to Treatment According to Postmenopausal Age and Dominant Site of Le~ions 
Lbs than 5 years More than 5 years 
Yiscer<~ Osseouo. Soft tis~ue Vi~cera Osseous Soft tissue 
Respon~e 
rem1ss1on 2 ( 11'/i) I (5'/rJ 2 (!4'/,) 16 (677t) 5 (219(} 20 (37%) 
~l<.lble 7 12 4 2 \3 18 
progre~~H)n 9 8 8 6 6 16 
Total number of paticnb 18 1 I 14 14 24 54 
Difference~ in remission rate~ between dominant sites for patients with menopausal ages of more than 5 years: Chi-square test P < 0.0 I. 
When adjusted for menopausal age and dominant 
site, this minor difference is far from statistical 
significance. No clear dose-effect relationship was 
apparent. 
However. there was a suggestion of this in the 
group of patients with a postmenopausal age of less 
than five years. The few remissions in that group 
were achieved only with the higher doses of 160-
180 mg daily. Because of small numbers and no 
randomization. definite conclusions are precluded at 
this time. 
Table 3 gives treatment results according to pre-
treatment body weight. In the non-obese group, the 
percentage of patients with progressive disease in spite 
of treatment is about twice that of the obese group 
(adjusted for menopausal age and dominant site; 
P ~ 0.05: Mantel-Haenszel test). 
Weight gain with megestrol acetate treatment has 
been reported. 1 In our series. a weight increase of 
more than 5% after six weeks of treatment was noted 
in 10% of the patients. This could be corrected 
by a dietary regimen of 1200 calories. Other side 
effects were negligible. No virilization was observed. 
Vaginal break-through and withdrawal bleeding oc-
curred in 11 patients (seven during and four after 
megestrol acetate therapy), which could be easily 
managed. Toxicity was not encountered. 
Discussion 
The finding that late postmenopausal patients re-
sponded more favorably to megestrol acetate treatment 
agrees with general clinical experience with other 
hormonal treatments. In this study, evaluation of 
response was made according to the dominant site of 
the lesions, 11 · 12 classified as soft tissue. osseous, and 
visceral disease. For survival prognosis, patients with 
visceral lesions were considered to have the poorest, 
and those with soft tissue metastases the best 
prognosis. If more than one system was involved, the 
one with the poorest prognosis determined the 
classification. Surprisingly, the best results were in the 
gro of patients classified as visceral. 
To investigate the reason for this unexpected finding, 
we studied the treatment responses of the separate 
anatomic sites (viscera, bones, and soft tissue). 
Treatment results for these sites in patients with a 
postmenopausal age of more than five years are 
given in Table 4. From this table, one can see that 
visceral and soft tissue lesions responded favorably to 
treatment, whereas only one remission was observed 
within the osseous group. Although 21% remissions 
were recorded for the group of patients classified 
'"osseous" according to dominant site, all but one of 
these remissions were due to responses of coincident 
soft tissue metastases. 
Further subdivision of patients with visceral dis-
ease showed that mainly lung metastases and in-
volved mucous membranes responded favorably (the 
latter is very important for the subjective improvement 
of patients). Liver metastases, on the other hand, re-
acted poorly. Because of the poor reaction of bone 
and liver metastases in this series, it would be 
worthwhile to search for good treatment schemes that 
TABU, 3. Pretreatment Body Weight and Response 
Pro" Ro-
misslon Stable we.~sion Total 
Obesity 2: I Y/( over 
kg/l(ml 
Total number of pallents 
32\2ll'7r) ~K(34'7r) 44(38'/i) 
14 (3:;r,;) 19 (45'/() 8 (20'}(} 
114 
41 
\55 
Weight was not known in five patients (bedridden out-patients). 
TABU:. 4. Tre<ttment Response of Separate Anatomical Sites: 
Postmenopausal Age of Patients more than 5 Years 
Re. Pro-
ffi!SS!Ofl Stable gression 
Visceral (24 patients) 10 (427o) 8 6 
Bone (3 I patients) I (3%) 24 6 
Soft tissue (77 patients) 35 (45%) 22 20 
Due to progression in another si!e, the response in one osseous 
and two soft tissue systems had not been documented. 57 
58 
36 
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• 34 
• 
• 
• 32 • 
• • 
•• •• 
• 
30 • ••• ••• 
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Fie. 1 ()UL'tckt·-, hot.ly ma~., im.k.\ at \(art of mcgc~tr\11 <KI.'latt: 
trcalm<'nl <!CCtli"ding to re~pon-,e <..:atcgory. IM.:an\ are indicated 
hy h<Jh.) 
combine different therapeutic modalities, e.g. hor~ 
mona! and chemotherapeutic agents. adjusted to the 
actual sites involved. it is hoped that more logical 
combination schemes can be developed in the future. 
Clearly, evaluation of treatment result5 classified 
according to ··ctominant :.ite," originally designed for 
survival prognosis'·~·a· 11 and not for responses of the 
actual benefit to the patients, is not sufficient. An 
additional classification as to separate anatomical 
sites '>eems mandatory. 
The observation that the obese group of patients had 
a higher re:--ponse rate needs confirmation by other 
studies. lfrep1 oducible, the finding may lead to a better 
understanding Jf mechanisms of action of additional 
hormonal treatment. To suggest or to offer hypotheses 
seems premarure at present. Our results confirm those 
of Ansfield 1: Megestrol acetate may be used at any step 
of sequential treatment. As there are hardly any side 
effects, it may be the first choice of treatment in late 
postmenopausal patients with soft tissue and lung 
metastases. Studies to determine the optimal dose 
are now in progress . 
Addendum 
Since this paper was submitted. we reviewed case records 
to obtain precise heights and pretreatment body weights of 
patients because of the apparent relationship between 
obesity and response rate (Table 3). In plotting Quete!et's 
body mass index {weight/height~). we found no great differ-
ences between the three response categories (Fig. 2). Al-
though the findings listed in Table 3 could largely be repro-
duced when patients with an index greater than ?.7 were com-
pared to those below that limiL a gradual increase of the 
percentage progressing with decreasing index was not 
apparent. On the basis of these results. it seems best to 
consider the suggested correlation between obesity and 
response as an incidental finding for now . 
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Estrogen, Androgen, Glucocorticoid, and Progesterone Receptors in 
Progestin-induced Regression of Human Breast Cancer' 
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Departments of Biochemistry [F. T., M S_ H., H_ P.j and Internal Medicine {H van G .. J A-F]. Rotterdamsch Radio-Therapeut1sch lnstltuut, Dr. Daniel den Hoed 
Kliniek, Groene Hilled1jk 301, 3075 EA Rotterdam, The Netherlands 
ABSTRACT 
A study was made of basic mechanisms involved in regres-
sion of breast cancer exposed to high levels of synthetic 
progestins. The possibility that progestins act on breast cancer 
by way of the progesterone receptor mechanism and subse-
quent increase of estradiol 1 7 #-dehydrogenase activity could 
not be confirmed in this investigation. It is demonstrated that 
the progestins megestrol acetate and medroxyprogesterone 
acetate are strong competitors for steroids which bind specifi-
cally to androgen, glucocorticoid, and progesterone receptors, 
indicating that the progestins are able to bind to these receptors 
with high affinity. In contrast, these progestins do not compete 
with estradiol for estrogen receptor binding. In 34 patients with 
progressive metastatic breast cancer, results of receptor stud-
ies have been correlated with clinical response during treat-
ment with megestrol acetate. Statistically, regressions were 
significantly associated with tumors containing large amounts 
of androgen receptors. Clinical correlation with the quantities 
of glucocorticoid receptor was weak, while such correlations 
with estrogen and progesterone receptors were absent. How-
ever, we did demonstrate relationships between the quantities 
of the various receptors in breast cancer. Tumors containing a 
large amount of androgen receptors also generally contain 
estrogen receptors. It might be that a favorable response to 
progestins is confined to the group of patients with hormone-
responsive breast cancers, as such characterized by the pres-
ence of estrogen receptors, and that within this group the 
actual androgen receptor levels determine response. 
INTRODUCTION 
Results of clinical trials have demonstrated that synthetic 
progestins such as MA3 are useful in the management of 
metastatic breast cancer (3, 4, 15). At our Institute. 160 pa-
tients with metastatic breast cancer have been treated w1th 
MA. Objective remission was found in 48 patients (30%), w1th 
median time until progression of 9.5 months (1 ). 
It has been suggested that steroid hormone receptors are 
involved in additive steroid therapy in breast cancer. In patients 
treated with estrogens. androgens. or glucocorticoids, objec-
l!•ie t--·r:wr regress;ons were obtained in 60% of the patients 
,,,11th pos1t1ve ER values, whereas only 8% ot the patients with 
' Th1s work has been f1nanc1ally supported by the Dutch NatiO!'Ial Cal'lcer 
League. the "Koningin Wilhelmina Fonds 
'To whom requests for reprints should be addressed 
"The abbrevtat1ons used are: MA. megestrol acetate: ER. estrogen receptor 
AR. androgen receptor; GR, glucocorticoid recept01; PR, progesterone receptor, 
E2DH, 17/3-estradiol dehydrogenase: DHT. 5a-dihydrotestosterone; PB. phos-
phate buffer (0.15 M Na,HPO.-KH,PO,, pH 7_4): MPA, medroxyprogesterone 
acetate 
Rece1ved December 26, 1979: accepted April 8. 1980 
negative ER values responded favorably (12). There is some 
clinical evidence, however, that breast cancer patients who 
respond to progestin therapy do not belong to exactly the same 
group as do those who respond to the conventional androgenic 
or estrogenic hormones (15). Furthermore, patients whose 
tumors were unresponsive to prior therapy with estrogens 
alone subsequently responded to a combination ot estrogen 
and progesterone (5, 14). 
In addition to ER, many breast cancer specimens contain 
AR, GR, and PR (7, 1 8, 19). The role of the various receptor 
sites in progestin therapy has not been established yet, and 
the mechanisms of action by which additive endocrine thera-
pies cause breast cancer regression are still not understood. 
In endometrial cancer, however, the observation that the activ-
ity of E2 DH increased during progestin therapy provided a 
basis for understanding the action of progestins (6, 13). E2DH 
activation results in a lower intracellular estradiol level and, 
consequently, reduction of estrogenic activity. Pellow et a/. 
(13) suggested that the PR mechanism is involved in E2DH 
activation by progestins. Furthermore, a decline of cytosolic 
ER levels was found during progestin therapy of endometrial 
cancer (6, 11 ). Llibbert and Poll ow (9) have recently demon-
strated the presence of E2 DH in human breast cancers. 
In this investigation, the E2 DH activity in breast tumors was 
studied, and the effect of MA administration on E2DH activity 
was examined in 6 patients. To gain some insight into the 
interactions ot progestins with the various receptors of breast 
cancer, the relative affinity of some progestins for these recep-
tors was determined. In a clinical study, tumor responses 
during MA therapy were correlated with the amounts of each 
of the various receptors in the tumors of a series of breast 
cancer patients. 
MATERIALS AND METHODS 
Breast Cancer Tissues. Breast cancer specimens were 
placed on ice immediately after surgery and transported to the 
pathology department where nontumorous tissue was removed 
and representatiVe samples were taken tor histological exami-
nation. Within 30 min after surgery, samples were frozen and 
stored until analysis in a -70° freezer or under liquid nitrogen. 
Chemicals. 17/:?-[2,4,6,7-3 H]Estradiol (90 to 115 Ci/mmol). 
17 ,B-{4-' 4 C]estradlol (50 mCi/ mmol), [1 ,2,4.5,6, 7 - 3 H]DHT ( 11 0 
to 150 Ci/mmol), and [6,7-3 H]dexamethasone (35 ~o 50 Ci/ 
mmol) were obtained from New England Nuclear Chemicals, 
Dreieich, W. Germany. [17o:-methy/-3 H]R5020 (promegestone; 
70 to 87 Ci/mmol) and unlabeled R5020 were kindly donated 
by Dr. J. P. Raynaud, Roussei-Uclaf, Romainville, France. 
Unlabeled steroids and other chemicals of analytical grade 
were obtained from Merck AG, Darmstadt. W. Germany, Serva 
Feinbiochemica. Heidelberg, W. Germany, and Sigma Chemi- 59 
60 
cal Co., St. Louis, Mo. Dextran T70 was obtained from Phar~ 
macia, Uppsala, Sweden, and Noble's agar was from Difco 
Laboratories, Inc., Detroit, Mich. 
Receptor Assays. Low-temperature agar gel electrophoresis 
according to the method of Wagner (19) was used, enabling 
simultaneous assessment of the various receptors. For analy-
sis, frozen tissue was pulverized under liquid nitrogen (Micro-
dismembrator: Braun, Melsungen, W. Germany) and, after 
thawing, homogenized in 10 mM Tris-HCI:1.5 mM EDTA:0.5 
mM dithioerythritol butter, pH 7.4. Cytosol (supernatant) was 
obtained by ultracentrifugation (I 00,000 x g, 60 min, 2"). 
Samples were prepared by incubation of cytosol with 3 H-ste~ 
raids for 2 hr at 4 c. Incubation concentrations of 3 H-Iigands 
were: 17j:?-estradiol, 10 nM: DHT, 30 nM; dexamethasone, 10 
nM: and R5020, 10 nM. Samples for correction of nonspecific 
binding were prepared by adding a 1 00-fold excess of unla-
beled 17{3-estradiol, DHT, dexamethasone, or R5020, respec-
tively, to duplicate samples. To reduce albumin binding, 17/3-
estradiol and OHT samples were treated after incubation with 
charcoal:dextran [0.5% (w/v) Norit A, 0.05% Dextran T70, and 
0.1°/0 gelatin in 10 mM Tris-HC1:1.5 mM EDTA:0.5 mM dithio-
erythritol buffer, pH 7.4Jfor 90 min, while R5020 samples were 
treated tor 15 min (17). Agar gel electrophoresis was per-
formed on 0.05-ml samples tor 90 min (21 VI em, 130 ma, 4 "). 
After electrophoresis, agar slabs were cut into 9 fractions at 
the cathodic side and 7 fractions at the anodic side of the 
origin. 3 H content of the fractions was determined by liquid 
sdntillation counting. Results of receptor assays are expressed 
as fmol/mg protein. 
Competition Experiments. In a typical experiment, an ex-
cess of tritiated ligand was added to a cytosol:buffer mixture 
together with varying amounts of unlabeled competitor in a 
range between 1 and 1 000 times molar excess over the radio-
actively labeled ligand. To enable correction for nonspecific 
binding, parallel incubations were made containing a 1 00-fold 
molar excess of unlabeled ligand. Binding data, corrected tor 
nonspecific binding, were expressed as percentage of the 
amount specifically bound in the absence of competitors. The 
results were plotted on a logit scale against the log competitor 
excess, and linear regressions were fitted to the data. The 
molar excess of competitor wh·lch causes 50% displacement 
of radioactive ligand was estimated as a measure of affinity of 
the competitor for the receptor, expressed as relative affinity. 
Assay of E2 DH Activity. E2DH activity was estimated in 800 
x g supernatants according to the method of Li..ibbert and 
Pollow (9) w"1th some mod"1f1cations. Frozen tissue was pulver~ 
ized and extracted at 4 o for 1 0 min with 4 parts PB (w /v). An 
800 x g supernatant was prepared by centrifugation (1 0 min). 
The standard reaction mixture contained 2 nmol [' 4 C]estradiol 
(dissolved in 0.025 ml methanol), 26 nmol unlabeled estradiol 
(dissolved in 0.01 ml methanol), 0.5 to 2.0 ml 800 x g super-
natant, and PB to make a total volume of 5.0 mi. This mixture 
was preincubated at 3JO for 10 min. The reaction was started 
by the addition of NAD+ (0.025 ml of an 80 mM solution in PB) 
and continued for 30 min at 3JO. [14C]Estradiol conversion was 
stopped by the addition of 0.05 ml of a mixture of 0.02 M 
estradiol and O.G? M estrone in methanol. The reaction mixture 
was then extracted 3 times with 5 ml chloroform:ether (1 :3, v/ 
v). Extracts were pooled and evaporated to dryness under 
nitrogen. The residue was redissolved in 0.2 ml chloroform and 
transferred quantitatively to a thin-layer plate (precoated Silica 
Gel 60 F254, 0.25 mm; Merck AG, Darmstadt, W. Germany). 
Estrone and estradiol were separated with a solvent system of 
chloroform: ethyl acetate (4:1, v/v). Radioactivity of separated 
steroids was quantitated on a radiochromatogram scanner (LB 
2721; Berthold, Wildbad, W. Germany). E2DH activity is ex-
pressed as nmol estrone formed per 30 min per mg 800 x g 
supernatant protein. 
RESULTS 
Competition Studies. Eight mammary cancers with known 
receptor concentrations provided cytosols for studying the 
affinity of MA for the various receptors. For comparative pur-
poses, the competitive effects of MPA and progesterone for AR 
and GR were also estimated. DHT, dexamethasone, and pro-
megestone (R5020) bind with high affinity to AR, GR. and PR, 
respectively, although cross-affinity may exist to some degree. 
To minimize interference of PR binding in experiments with EA. 
AR, and GR, cytosols were selected containing small amounts 
of PR (Table 1 ). 
WithER, no significant displacement of radiolabeled estradiol 
by MA or MPA could be detected. MA competed well for PR, 
AR, and GR (Chart 1 ). The relative affinities of MA for PR, AR, 
and GR were 3, 4, and 8, respectively. MPA was found to 
compete slightly more strongly for AR and GR (relative affini-
Table 1 
Concentrations of vanous receptors m breast cancer cytosols used m the 
competition studies 
ER. AR. GR. and PR were estimated by low-lemperature agar gel electropho-
rests 
Tumor 
Used in experi-
ments for CR AR GR PR 
198 ER 6.200 675 --~~--~ 
217 PR 1.470 810 200 2.620 
253° PR 630 380 470 21.800 
368 AR 2.180 780 770 120 
424 GR 1.080 75 525 285 
475 GR 290 NO 810 NO 
503 AR. GR 635 370 400 920 
-;;-i~;i~--~onc-~ntra;i:ros of th;"~·;~~·;o:~ 1 ~~-~-;;·'c,8-,:-m--:c8~:-o~~ 19.5 :::ml 
cytrpol 
c NO, not detectable 
Tumor 253 was obtairoed from a patient receiving low-dose estrogen ther-
epy 
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Chart 1 Competition of MA. MPA. arod progesterone (P) for AR. GR. ar1d PR 
of human breast caflcers. Numbers refer to tumor roumbers. For each type of 
receptor. lhe binding data. expressed as percerotage of specifically bound 
tritiated ligand, are plotted on a logit scale as furoction of the tog molar excess of 
competitor. These progestins did not compete significantly for the ER OEX. 
dexamethasone 
ties, 2 and 3, respectively). The capacity of progesterone to 
compete for AR and GR (relative affinities, 45 and 71, respec-
tively) was considerably lower. 
E2DH Activities in Breast Cancer Specimens. To demon-
strate the presence of E2DH in breast cancer, the capacity of 
BOO x g supernatants to oxidize estradiol in the presence of 
NAD+ was determined in some arbitrarily chosen specimens. 
E2 DH activity was observed in 1 0 of 1 0 primary tumors and in 
2 of 4 metastatic deposits. 
We were in the position to make a pilot study of the E2 DH 
activity in metastatic tissues of 6 advanced breast cancer 
patients before as well as during MA therapy. The E2DH deter-
minations in the consecutive samples, which were kept at 
-70° until analysis, were performed simultaneously. The re-
sults are shown in Table 2. Prior to therapy, E2 DH activity was 
present in 4 tumors and absent in the tumors of 2 patients. No 
significant increase in E2 DH activity during therapy was ob-
served in any of the patients, although tumor regression was 
reported in 4 of them. 
Correlations between Receptors and Clinical Response. 
The response to MA administration (daily dose, 160 to 180 mg 
p.o.) was assessed in 34 postmenopausal breast cancer pa-
tients with progressive disease in whom one or more of the 
receptors had been determined. Therapies lasted for at least 
6 weeks, and objective criteria for the assessment of response 
could be used inasmuch as these patients had other lesions to 
document the response. Clinicians who evaluated response 
were unaware of the receptor contents of the tumors. Objective 
remissions, defined according to the criteria of the EORTC 
Breast Cancer Cooperative Group, were obtained in 1 7 pa-
tients. The duration of remission varied from 2 months to more 
than 23 months. 
In Chart 2, the distributions of the respective receptors are 
compared in patients in whom remission occurred (responders) 
and in those with stable or progressive disease (nome-
spenders). 
Statistical tests revealed a significant difference between 
these groups in the distributions of the amounts of AR ( p = 
0.01, Wilcoxon test). A weak correlation was also found with 
GR ( p = 0.07), but there were no statistically significant 
relationships between clinical responses and quantities of ER 
and PR {p = 0.34 and 0.24, respectively). While 7 of 17 
tumors of responding patients did not contain a measurable 
amount of PR, this was the case in only 1 of 12 tumors of the 
nonresponders. This difference is of borderline statistical sig-
nificance (p = 0.1}. 
As reported earlier (16), we found relationships between the 
amounts of ER, AR, and GR in breast cancer. In this paper, 
Table 2 
E2DH activity in breast cancer specimens taken subsequently before and during 
MA administration 
No. of 
Patient Clinical response days a 
540 Regression 7 
569 Regression 5 
591 Regression 7 
564 Regression 6 
581 Progression 7 
532 Stable 84 
E2 0H (nmol estrone; 
30 min/mg protein) 
Before During 
0.17 0.19 
0.13 0.15 
0.13 0.14 
N0° NO 
0.24 0.24 
NO NO 
: ~~~~~; ~!t~~~=b~:tween start of therapy and takmg of second biopsy 
these associations, including those with PR, are demonstrated 
with results of all receptor analyses in breast cancer as per-
formed at present in this laboratory. Associations between the 
quantities of the several receptors were ::::valuated using the 
rank correlation coefficient of Kendall (Table 3}. All relation-
ships, except GR-PR, were found to correlate in a statistically 
significant manner, although the associations are not strong. 
Similar associations occur in the receptor values of the 
present study. All tumors without PR contained no ER or only 
small amounts of ER (<60 fmol/mg protein). It is of interest to 
note that all patients with AR levels above a cutoff level of 30 
fmol/mg protein were responders. Their tumors also contained 
ER (range, 12 to 750 fmol/mg protein) and GR (range, 15 to 
30 fmol/mg protein), but PR was present in only 5 of 7 cases 
(range, 0 to 250 fmol/mg protein). In our larger tumor material, 
44 of 111 tumors obtained from postmenopausal women con-
tained over 30 fmol AR per mg protein. Of these, 40 specimens 
also contained ER in varying amounts, 
Two remissions were associated with malignant tumors de-
void of AR. The best explanation for an unexpected finding of 
a clinical remission associated with a tumor lacking receptors 
might be that the specimen was obtained from a patient having 
receptor-containing as well as receptor-lacking metastases. 
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Chart 2. For each type of steroid hormone receptor, the quantities, expressed 
as fmol/mg protein, are compared between responders (R) and nonresponders 
(F) to MA administration. The p values given (2-sided) are from the Wilcoxon 
test. corrected for ties. 
Table 3 
Relationships between the qu,antities of the v,arious receptors in breast c,ancer 
ER, AR. GR, and PR were estimated by low-temperature agar gel electropho-
resis. Total number of patients, 237; mean age, 59 years. Premenopausal, 19%: 
postmenopausal. 64%: castrated. 16%. Primary tumors, 32%: metastatic tumors, 
68%. 
Kendall rank 
correlation 
Set No of patients coefficient p 
ER-PR 155 0.23 <0.0001 
ER-AR 174 0.29 <0_0001 
ER-GR 180 0.26 <0.0001 
AR-PR 113 0.22 0.0003 
AR-GR 164 0.31 <0.0001 
GR-PR 118 0.03 0.33 61 
62 
DISCUSSION 
The possibil'ity that tumor regression in breast cancer during 
MA administration proceeds by mechanisms as postulated for 
endometrial cancer is contradicted by some observations in 
the present study. As demonstrated, many but not all breast 
tumors possess in vitro capacity to oxidize estradiol. However, 
no significant increase in E2 DH activity was observed during 
MA therapy. Furthermore, in the clinical correlation study, 7 of 
1 7 responders lacked PR in their tumors. which contradicts the 
suggestion that the presence of PR is required for MA action 
on breast cancer. 
From the competition studies, it may be concluded that MA 
competes strongly with DHT, R5020, and dexamethasone tor 
AR, PR, and GR, respectively. The high-affinity character of 
binding was also demonstrated recently by Maclaughlin and 
Richardson (1 0), who, using tritiated MPA, found dissociation 
constants of 6 x 1 o- 10 and 5 x 10- 10 M, respectively, for the 
binding to PR and AR. It appears that MA and MPA have a 
broad receptor specificity, while other steroids interact mainly 
with only one of the receptors. Therefore, part of the specificity 
of binding of steroids is determined by their configuration and 
not solely by the configuration of the receptor binding sites. 
In the present study, an estimate of the receptor quantities 
was made using a single concentration method. With such a 
method, underestimation of the available number of receptor 
sites will occur due to equilibrium kinetics. However, no attempt 
was made to correct for underestimation. In the present study, 
the receptor amounts are handled by rank-order statistics. 
As demonstrated, the quantities of the various receptors 
found in breast cancers are positively associated with each 
other, although the relationships are rather weak. With increas-
ing amo· 1ts of ER, there is a corresponding increase in the 
quantities of the other receptors. Recently, Allegra et at. (2) 
reported similar observations with their population of breast 
cancer patients. In contrast to their study, we found no corre-
lation between the quantities of GRand PR. 
There may be a link in the regulation of synthesis of the 
various steroid hormone receptors, but secondary regulation 
mechanisms also appear to be present. This is demonstrated 
by Patient 253 (Table 1 ), who received low-dose estrogen 
therapy preceding receptor determinations. The tumor con-
tained a very high level of PR"s, but low or moderate levels of 
the other receptors. It was hypothesized by Horwitz et a/. {8) 
that PR synthesis in breast cancer is estrogen dependent. 
It may be doubted that ER is actively involved in the mecha-
nism of action of progestins, since the competition studies 
ruled out the importance of ER binding. However, due to the 
above-mentioned relationsh-IPS in the quantities of the various 
receptors, tumors with high AR levels may largely coincide with 
ER-containing tumors. Indeed, most (40 of 44) of these tumors 
contained varying amounts of ER. 
In view of these data, it would appear that EA may be a 
marker for hormone responsiveness of a tumor, irrespective of 
its role in the regression mechanism. Responsiveness to a 
particular type of endocrin8 therapy, however, may actually be 
determined by one {or more) of the various receptors. 
Data from the present study suggest that AR is directly 
involved in MA-induced regression and that AR acts as a 
receptor for MA. Furthermore, a high concentration of AR, and 
not merely its presence, appears to reflect the sensitivity of 
mammary cancer to MA. A similar observation was made for 
endometrial cancer, inasmuch as remissions during progestin 
treatment were reported to be associated with high PR contents 
of the tumors (20). 
This suggests that suppression of tumor growth occurs in 
cases where a sufficiently high number of receptor:progestin 
complexes are translocated to the tumor cell nuclei. One may 
hypothesize that a high nuclear concentration of these com-
plexes is necessary to compete adequately with nuclear recep~ 
tors tor acceptor sites. As a result, some transcription 
processes operative in hormone responsive tumor cells may be 
inhibited. 
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CHAPTER IV 
Steroid Receptors m Megestrol Acetate Therapy 
J. Alexieva-Figusch, F. A. G. Teulings, W. C. J. Hop, 
J. Blank-van der Wijst, and H. A. van Gilse* 
Department of Internal Medicine, Rotterdamsch Radio-Therapeutisch Instituut, 
Dr. Daniel den Hoed Kliniek, Groene Hilledijk 301. 3075 EA Rotterdam, The Netherlands 
Introduction 
The role of megestrol acetate (17a-acetoxy-6-methyl-pregna-4.6-diene-3,20-dione), a 
synthetic progestin derived from hydroxyprogesterone, in the treatment of advanced breast 
cancer has long been established: generally. remission can be achieved in ca. 30% of 
postmenopausal patients [1-3, 12, 13, 16. 18, 19]. It is difficult to define the physiological 
and pharmacological effects of progesterone and synthetic progestins, since virtually none 
of them are due exclusively to these hormones. Nevertheless, while estrogens and 
androgens have mainly growth-stimulating effects, the action of progestins is directed more 
towards modification and differentiation [14]. Megestrol acetate has been studied in both 
man and animals and seems to have antiestrogenic, antiandrogenic. and glucocorticoid-like 
properties [4-8. 10, 15] (Fig. 1). There is little information correlating the effect of 
rnegestrol acetate treatment and receptor content in human tumor tissue. Morgan reported 
response to megestrol acetate in seven of 16 patients with ER + and in two of five patients 
withER- [13]. In our previous study on steroid receptors in megestrol acetate-induced 
regression of human breast cancer [17]. it was demonstrated that megestrol and 
medroxyprogesterone acetates are strong competitors for steroids which bind specifically 
to androgen, glucocorticoid. and progesterone receptors, indicating that these progestins 
fH3 
C=O O 
crJI ·O-~-CH3 
I 3 
o'l : 
CH3 
Fig. 1. Megestrol acetate 17 a- ocetoxy - 6 - methyl - pregno -- 4,6 - diene - 3,20 - dione 
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analysis, and Mrs. A. Sugiarsi. Mr. P. van Assendelft, and Mrs. J. L. Wike-Hooley for their 
assistance 65 
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are able to bind to these receptors with high affinity. In contrast, they do not compete with 
estradiol for estrogen receptor binding. Regressions we.re significantly associated with 
tumors containing large amounts of androgen receptors, tumors which also generally 
contain estrogen receptors. 
The possibility that megestrol acetate acts on breast cancer via the progesterone receptor 
mechanism with subsequent increase in estradiol 17fi-dehydrogenase could not be 
confirmed, although the presence of estradioll7fi-dehydrogenase in human breast cancer 
has been demonstrated [11]. 
The present study correlates steroid receptors to response in primary and metastatic breast 
tumor tissues of 60 postmenopausal patients treated with megestrol acetate. 
Materials and Methods 
One or more steroid receptors were assessed in 22 primary and 38 metastatic breast cancer 
specimens. Estrogen receptor was determined in 59 patients, androgen in 32, glucocor-
ticoid in 34, and progesterone in 45. Tumors were classified as receptor negative if they 
contained less than 10 fmoVmg protein. The receptor assay methods used have been 
reported previously [17]. 
Some characteristics of the patients in this study are shown in Table 1. At the start of 
treatment all patients .received megestrol acetate for progressive disease as objectively 
demonstrated by appropriate clinical and biochemical investigation. After 6 weeks of 
Table 1. Characteristics of the 60 patients whose tumors were assayed 
for steroid hormone receptors 
Mean age in years (range) 60 
(32-86) 
Menopause age 
1-5 years 25 
> 5 years 35 
Disease-free interval 
0 months 10 
1-12 months 14 
13-24 months 19 
25-36 months 7 
> 36 months 10 
Previous hormonal therapy 21 
No previous hormonal therapy 39 
Dominant sites 
Soft tissue 28 
Bones 21 
Viscera 11 
Response to rnegestrol acetate therapy 
Remission 20 (33%) 
Stable disease 24 (40%) 
Progression 16 (27%) 
treatment. response was assessed according to EORTC criteria [9]. The clinicians who 
evaluated response were unaware of the receptor contents of the tumors. 
Megestrol acetate (Niagestin 15) was given in daily oral doses varying from 120 to 180 mg in 
four equal fractions. The drug was continued until the disease progressed. 
Results 
In our series of 60 patients treated with megestrol acetate, we found the following: estrogen 
receptor positivity in 64%, progesterone receptor positivity in 56%, glucocorticoid and 
androgen receptor positivity in 53% and 56% respectively. With increasing amounts of 
eStrogen receptor there was a corresponding increase in the quantities of the other 
receptors. 
Figure 2 gives estrogen receptor data according to response to treatment. Neither the 
presence of the receptor nor its amount was demonstrably related to the outcome of 
treatment. However, the duration of remission in patients with estrogen receptor-positive 
tumors was significantly longer (log-rank test: P < 0.01) than in those who lacked estrogen 
receptor (Fig. 3). 
Figure 4 gives data on androgen, glucocorticoid. and progesterone receptors in relation to 
treatment outcome. A statistically significant higher amount of androgen receptor was 
noted in the group with remission as compared with the group with stable or progressive 
disease (Wilcoxon test: P < 0.05). No correlation between response to treatment and the 
amount of glucocorticoid or progesterone receptor was demonstrated. Remission in the 
group of patients with androgen receptor exceeding 30 fmollmg protein was 60% (six of 
10), while in the group with androgen receptor below that limit the figure was 23% (five of 
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Fig. 2. Response to megestrol acetate treatment according 
to estrogen receptor values. R, remission; S, stahle; P, 
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Fig. 4. Response to megestrol acetate therapy according to androgen (AR), glucocorticoid (GR), and 
progesterone (PRJ receptor values. R, remission: 5. stable; P, progression 
22). Moreover. the duration of remission in the group with a high androgen receptor level 
(> 30 fmol/mg protein) was significantly (log-rank test: P = 0.05) longer than that in the 
group with a low value ( < 30 fmol/mg protein) (Fig. 5). The results given in this section did 
not appreciably differ between patients according to whether receptors were evaluated in 
primary or in metastatic tumor. 
Fig. 5. Actuarial percentages of 
patients in remission according to 
amount of androgen receptor ( AR) 
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Steroid hormone receptors are found in a variety of cancers, including human breast 
cancer. For megestrol acetate therapy it seems that only the androgen receptor may be 
useful as an indicator of response. Moreover. this study strongly suggests that a satisfactory 
remission (i.e., of long duration) may be expected in cases with a large amount of androgen 
receptor. None of the other receptors appear to predict the probability of remission to 
megestrol acetate. 
The fact that long remissions are associated with estrogen receptor~positive tumors might 
be explained by the correlation between amounts of androgen and estrogen in breast 
tumors. All tumors high in androgen receptor were also estrogen receptor positive. 
However, the number of patients studied is too small to assess fully the additional value of 
estrogen receptor once the androgen receptor level is known. 
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CHAPTERV 
Treatment of Metastatic Breast Cancer Patients 
with Different Dosages of Megestrol Acetate; Dose 
Relations, Metabolic and Endocrine Effects* 
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Abstract-iHegestrol acetate (A1A) is of therapeutic value in breast cancer pallf'nl.l. 
This study was designed to evaluate the effects of differf'nt dosages of AIA on 
endocrine events potentially influenced by the drug in relation to plasma ln·el of 
!'viA and clinical effects in patients with advanced breast cancer. Eightern 
postmenopausal patients were randomly distributed over six groups to receive daily 
90. 180 or 270 mg of MA (l\liagestin®) orally in a cross-over study consisting of 3 
periods of 6 weeks. Complete remission was obsen,ed in 1 patient, partia I remisswn 
in 9, no change in 4 and failure in 4 patients. Durmg the 18 weeks of treatment 
plasma levels of MA gradually increased, irrespectwe of the dose admini.1tered. 
Significant rises of the basal and TRH-stimulated plasma PRL and basal insulin 
levels were observed, whereas LH and FSH, rstradiol, SHBG- and the 
pituitary-adrenal axis were suppressed. None of the~e mrtabolic effects showed a 
correlatwn with the clinical response. We concluded that treatment of metasta/i( 
breast cancer with 180 mg /vi Alday is effective and causes minimal advnse rffect.\. 
INTRODUCTION 
THE SYNTHETIC progestin megestrol acetate 
(MA) ( 17 a-acetoxy-6a-methy 1-pregna-4 ,6-diene-
3,20-dione) is effective in the treatment of patients 
with advanced breast cancer [I, 2]. The mech-
anism through which MA exerts its effects on 
mammary tumors is unclear. The drug has been 
reported to display progestin-, glucocorticoid-like 
and androgenic properties [3, 4]. An attempt to 
explain the action of MA through a progesterone-
receptor-mediated increase in estradiol dehydro-
genase activity in the tumor specimens of post-
menopausal breast cancer patients was un-
successful. Only a very low affinity of MA to 
estrogen receptors was observed, but the drug 
bound relatively well to progesterone, androgen 
and glucocorticoid receptors [5]. This study was 
designed to evaluate the effect of oral administra-
tion of 3 different dosages of MA on the plasma 
Accepted II J unr 1983. 
*Partly presented at VIIIlh Dutch-British Endocrine Meeting 
25th-27th August 1982. 1\"oordwijkerhout. Tht Netherlands. 
concentrations of gonadotropins, prolactin 
(PRL), growth hormone, estradiol, sex hormone 
binding globulin (SHBG ), insulin and glucose, 
on adrenocortical function and to investigate 
relationships between plasma levels of MA and 
clinical responses during the treatment of 
metastatic breast cancer. 
MATERIALS AND METHODS 
Patients 
Eighteen patients with evaluable and measur-
able advanced breast cancer, who had not yet 
otherwise been treated, were selected for this 
study. Informed consent to participate in this 
study was obtained from all patients. All were 
more than 2 yr after their natural menopause and 
between 54 and 75 yr of age. All patients except 
one (ascites with gastrointestinal discomfort) 
were in good general condition, without gastro-
intestinal-, hepatic- or renal disease, diabetes 
mellitus or malabsorption. The patients received 
three 6-week treatments with daily doses of 90, 180 
and 270 mg of megestrol acetate (Niagestin®, 71 
72 
supplied by NOVO, Denma:rk) in a cross-over 
regimen. Medication was taken orally with 8-hr 
intervals (07.00-15.00-23.00). When definite pro-
gression of metastatic cancer occurred, the drug 
was withdrawn. At the start and end of each 
treatment period, romine clinical and biochemical 
investigations were performed. In addition, blood 
was collected for the estimation of the plasma 
concentration of MA (at 14.80), basal gonado-
tropins, grOwth hormone, estradiol, SHBG, 
prolactin (PRL) and TSH before and after 
administration of 200 J.Lg of TRH intravenously, 
11-deoxycortisol before and after 6 X 750 mg of 
metyrapone and insulin and glucose during a 
glucose tolerance test (100 g of glucose orally). 
Fifteen fully evaluable patients completed the 
study, which allowed statistical analysis with 
respect w the endocrine parameters. Clinical 
evaluation \vas done after each period of 6 weeks 
based on UICC criteria of response with regard to 
visceral, osseous and soft tissue metastases [6]. 
Laboratory methods 
For the radioimmunological assay of MA in 
plasma, an anti-?v!PA-3-(o-carboxymethyl)oxime-
bovine serum albumin serum, which cross-reacts 
extensively with MA, was used [7, 8]. Blood 
samples were taken before and at the end of each 
treatment period just before the administration of 
the drug. LH and FSH were measured by specific 
radioimmunoassay, using materials from KABI 
(Stockholm, Sweden). Results were expressed as 
U/1; normal values for postmenopausal women 
were for LH more than 21.0 and FSH more than 
5.0 U/1 respectively. Plasma PRL levels were 
determined by a double-antibody radioimmuno-
assay method using the kit from IRE (Antwerp, 
Belgium). One nanogram of the standard 
employed is equivalent to I ng of the standard 
VLS/1 of the NIH. The upper limit of normal in 
women is IS ng/ml. Blood samples were taken at 
0, 20, 30, 60 and 120 min after 200 J.Lg of TRH 
given i.v. before and at the end of each treatment 
period (at 09.00-11.00 a.m.). In addition, TSH 
estimation was performed. TSH was determined 
by radioimmunoassay, using the kit from DPC 
(U.S.A.). Normal values are lower than 10 J.LU/ml. 
Plasma levels of growth hormone were determined 
by a double-antibody radioimmunoassay using 
the CEA kit (Paris, France). Normal basal fasting 
levels are 1-5 ng/ml. Estradiol was measured by 
radioimmunoassay [9]. 11-Deoxycortisol (com-
pound S) was estimated in plasma by a 
competitive protein binding assay following a 
simple solvent extraction before and 24 hr after 
6 X 750 mg metyrapone given orally. The normal 
value after metyrapone exceeds 15 J.Lg/100 ml [10]. 
The capacity of the serum to bind eHJ-
dihydrotestosterone was used as a measure for the 
concentration of SHBG and was determined by 
agar gel electrophoresis [ll]. Total immuno-
reactive insulin was determined using ethanol 
extraction, whereby antibody-bound immuno-
reactive insulin is dissociated and separated 
together with the free insulin from the serum 
proteins and antibodies [12]. Glucose was 
estimated enzymatical!y. 
Statistics 
Dose-effects for the various parameters were in 
the first instance investigated by multivariate 
methods appropriate for change-over designs 
[13]. These methods, in addition to dose-effects, 
allow for individual differences, differences 
between the 3. treatment periods and residual 
effects from the treatment with a particular dose 
in the previous period for periods 2 and 3. These 
analyses were supplemented by standard non-
parametric tests (the Friedman test, the signed 
rank test and the rank sum test). P values given in 
the text and figures arose from these non-
parametric tests. 
RESULTS 
Clinical response 
Complete remission after 18 \veeks was 
achieved in l/18, partial remission in 9/18 and 
stable disease in 4/18 patients while progression 
occurred in 4/18 patients. Favourahle effects of 
MA have been found in all types of metastases, e.g. 
in soft tissue, bone and viscera. J\'o patient had 
liver metastases. During the study period no 
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Fig. 1. Conrentralwn of megestrol acetate (/VIA) in plasma of 
breast cancer jJa/lents treated unth d1fferent daily doses of kiA 
for 3 periods of 6 weeb_ Individual values are gitwn as a 
functwn of the tzme after the start of the exprrimenl, and with 
respect to the dosage of MA recnved during the 6 weeks 
immedwtely preredmg the blood sampling. 0:90 mgiday: X· 
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Tab /e l. Plasma concentrations of megestrol acetate and endocrine parameters 
in patients with metastatic breast cancer responsive (CR+PR) or refractory 
(l''"'CH+F) to treatment with megestrol acetate 
Mean v<Jlue of plasma 
concentration at 6 we<,b 
:\lege;trol acetate (ng_-m)J 
Bas;ll prolactin (ng·ml) 
Basal TSH (/.<ll:ml) 
Basal growth hormone (J.Lg-'l) 
LH (U·l) 
FSH ((: i\) 
Estradtol (pmoL l) 
11-Deoxycortiso\ {J.Ig "100 mli after metyrapone 
SHBG {111110\ "lJ 
Basal imulin (J.It.: -'ml) 
Basal glucose (mmo\."]) 
adverse effects of the drug have been observed; MA 
was tolerated excellently at all 3 dosages. 
!Vlegestrol acetate concentration in plasma 
The concentrations of MAin plasma increased 
with time during the treatment (Fig. l, P < 0.01 ). 
No relation could be demonstrated between dose 
and plasma level, even if corrected for body 
surface. Therefore the results for the different 
dosages were combined to give median values of 
134, 170 and 243 ng/ml after 6, 12 and 18 weeks 
respectively. No relation to the clinical response 
has been found; plasma levels of failures did not 
differ from those in responders (Table I). 
In 5 other patients who gradually discontinued 
long-term treatment with 180 mg MA (within 18 
.days), plasma levels of MA 3 days after complete 
cessation appeared decreased from 243 ± 25 
(S.E.M.) during the steady state to 17 ± 7 ng/ml. 
Responders 1\" on-responders 
(n = 10) (n =8) p 
125 174 0.1 
10.7 18.6 0.1 
7 .l 5.1 0.2 
4.4 9.3 0.4 
20.8 15.0 0.8 
15.9 10.0 0.9 
57.8 67.0 0.06 
'.9 2.8 0.9 
57.8 52 0.5 
23.1 20 0.4 
5.1 4.8 0.4 
Endocrine effects 
Prolactin. Before the stan of the treatment basal 
plasma PRL levels were normal in all patients, 
while there was a normal reaction of PRL to TRH 
(Fig. 2). During treatment with MA the mean 
basal PRL levels increased significantly from 
7.1 ± 0.8 to 13.9 ± 2.2 ng/ml (Table 2, P < 0.001 ). 
There was also a hyper-response of PRL to TRH 
during treatment with MA. The range of the 
response of plasma PRL to TRH varied widely 
(Fig. 2). 
TSH and growth hormone. Plasma levels of 
TSH were measured before and after TRH 
stimulation. There was no change in the basal 
and stimulated TSH levels during MA treatment. 
Basal mean TSH level was6.6 ± 1.8 J..LC/ml before 
treatment and 6.2 ± 0.6 J..LL'/ml after 6 weeks of 
treatment. In addition, TSH response to TRH 
was not altered during MA treatment. Basal 
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Fig. 2. Crmrnrtration of prolai/in (P/?.1.) m plasma of brea.1/ (n!I(I'T pat/fillS /reatni u·tth dtf(errnl do.\age' of 
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Table 2. Response of plasma prolactin to TRH 
admiruslration (200 }-!g i.<.J.) in patients with metastatic 
breast cancer before and after a 6"week treatment with 
megestrol acetate 
·rime after Prolactin (ng;ml) 
TRH (mean± S.E.M. n = 18) 
(JTI][]) Beton: treatment After treatment p 
0 7. I ± 0.8 !3.9 ± 2.2 0.001 
20 71l.9 ± l.'i.2 !57.2 ± -tl .1 :-.iS 
:lO 60.5±11.0 128.-1 ± 29.4 l\'S 
60 28.··J ± 4.2 51.5 ± 9 .. ) l\S 
120 !2.1 ± 2.4 17.0±2.3 0.005 
plasma growth hormone was not influenced by 
the use of MA. The mean value before the 
treatment was 5.8 ± 1.2 ,ug/1; after a 6-'"'eek period 
the plasma concentration of growth hormone was 
6.4 ± 1.8 pg/L 
Gonadotropins. All doses of MA used caused a 
significant decrease (P < 0.001 l of the basal 
plasma concentrations of LH and FSH after 6 
weeks (Fig. 3 ). Before treatment the mean 
concentrations of LH and FSH '"'ere 46.6 ±4.5 
and 28.0 + 3.0 U/l respectively. After 6 weeks o! 
treatment these mean values were 18.4 ± 2.9 and 
13.4 ± 2.6 U/1 respectively. The inhibition of 
gonadotropin levels ·was identical with all three 
doses of MA without exception during the whole 
period. 
Estradiol and SHBG. All doses of MA caused a 
significant decrease (P < 0.001) of plasma estradiol 
concentrations after 6 weeks of treatment (Fig. 3 ), 
'"'hich persisted throughout the whole treatment 
period. The mean concentration was 79 ± 6.3 
pmol/1 before and 62 ± 2.5 pmol/1 after the 6-
week period. This inhibition did not differ in the 
three dose-groups. 
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6 X 750 mg of metyrapone 111 pallerlls U'ith advanced breast 
cancer. Tlu' mNyrapone teo/ was performed l:wfore and after a 
6-week lrea.tmerlf course wtlh megrslro/ aceta/e. 
A significant decrease (?<0.001) m the 
concentration of SHBG was found after 6 weeks 
(Fig. 3). During the study periods a weak 
correlation (P < 0.02) between SHBG concentra-
tion and the dose administered appeared to be 
present. 
l!-Deoxycortisol (compoundS). Plasma levels 
of ll-deoxycortisol before as well as after 
6 X 750 mg metyrapone orally showed a signi-
ficant decrease during MA therapy (Fig. 4). 
During treatment with 90 mg daily 3 out of 6 
patients still shm\'ed a detectable increase of 
plasma compound S (to 9.0, 14.9 and 13.6~-tgl 
lOO ml), while these levels remained completely 
suppressed after metyrapone administration 
during treatment with ISO and 270 mg MA/day. 
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Table 3. Results of a prolonged glucose tolerance test in patients with metastatic breast cancer 
before and after a 6-week treatment course with megestrol acetate (i\.1A) 
Glucose (mmoL I) lnsulm (/.tl".·ml) 
0 he I he 2 he :) hl 0 he I h• 2 hr 5 hr 
Before treatment 5.5 9.7 8.4 n 17 122 147 20 
(0.2) (0.6) (0.7) (0.2) (1.6) (2!A) (23.7) (2.7 I 
After 6 weeks of MA 4.9 9.7 8.8 ·1.4 22 162 203 32 
(0.1) (0.8) (0.5) (0.2) (1.7) (30.3) (27.2) (6.·1} 
p 0.002 0.01 0.04 
After 6 weeks of· 
90 mgo( MA 5.0 9.7 8.6 4.8 18 127 I 55 19 
(0.1) (2.1) (0.9) (0.3) (2.8) (4.?. 7) (36.6) (4.21 
180 mg of MA 4 7 8.8 8.7 44 22 96 151 S·J 
(0.2) (0.7) (0.7) (0.6) (3.1) ( 11.7) ( 18.1) (24.3) 
270 mg of :..fA 5.2 10.5 9.1 4.2 26 256 .30S 31 
(0.2) (I .1} (0.9) (0.3) (3.3) {72.8) 1."!8.8) (7.4) 
Results are expressed as me<Jns (n = 18). 
Standard errors of the me<~n (S.E.M.) are given in parentheses. 
Insulin and glucose 
Insulin and glucose in plasma were estimated 
before and at l, 2 and 5 hr after oral administra-
tion of 100 g of glucose. Mean basal plasma 
glucose and insulin levels before the treatment 
were 5.5 mmol!l and 17 .uU/ml respectively 
(Table 3 ). After 6 weeks ofMA treatment the mean 
basal glucose was significantly decreased (P < 
0.002), whereas the concentration of insulin 
before (P < 0.01) and 5 hr after (P < 0.04) glucose 
administration was significantly increased. The 
increase of basal plasma insulin appeared dose 
dependent(,, ~0.71, P~0.002). 
DISCUSSION 
The results of this study demonstrate that 
treatmem of metastatic breast cancer with 
megestrol acetate (MA) induces multiple changes 
in the hormonal environment of the tumor. The 
drug caused significant increases in basal plasma 
prolactin and insulin and decreases in basal 
plasma LH, FSH, estradiol and SHBG, and a 
suppression of the pituitary-adrenal axis. Some 
of these parameters changed slightly in a dose-
dependent way. There was no relation between 
these changes and the clinical response. 
The study was designed as a cross-over regimen 
in order to obtain extensive information from a 
limited number of patients. Treatment periods of 
six weeks were chosen since this period is the 
minimum time span required for the evaluation 
of the clinical reponse. Based on data from the 
available literature obtained after administration 
of a single dose of 60 mg of MA [14-16), it was 
anticipated that steady-state plasma levels of MA 
would be achieved very soon after initiation of 
treatment or cross-over to a different dose. The 
excretion of a single dose of MA has been reported 
to be essentially complete \vi thin 4-7 days [I 7]. 
Our observation that plasma MA 3 days after 
complete withdrawal was decreased by 93 ± 2% of 
the steady-state level further justified the choice of 
a 6-v-;eek cross-over intervaL In contrast to our 
expectation, however, we found an accumulation 
of MAin the plasma of the patients, irrespective of 
the order in which the different dosages were 
administered (Fig. I). Moreover, for the doses 
used, no relation was found between the plasma 
concentration of MA. and the clinical response 
(Table l ). Based on these observations, an exact 
therapeutic level forMA cannot be derived from 
plasma levels of MA alone. The 10\vest plasma 
level of MA associated \vith an objective response 
was 65 ng/ml. \Vhen the observed metabolic and 
endocrine effects are taken into account an 
optimal dose v.rith minimal adverse effects can be 
defined. Treatment with a daily dose of 270 mg of 
MA caused an undesirably high basal concentra-
tion of insulin, whereas treatment with 90 mg 
daily \vas not sufficient to completely suppress the 
pituitary-adrenal axis. Such a suppression seems 
to be desirable, because a glucocorticoid effect 
may be important for the mechanism of action. 
Therefore, we advocate the use of 180 mg of 
MA/day. This dose is in agreement with the doses 
reponed by other investigators [2, 18, 19]. Our 
results are the first to provide a rationale for this 
dose. When compared to the structurally related 
progestin medroxyprogesterone acetate (MPA), 
which is also frequently used, MA has several 75 
76 
advantages. Firsdy, much lower oral doses of MA 
than of MPA are required [20, 21] to reach 
therapeutic levels of the drugs (roughly, above 100 
ng/ml). This is probably due to the presence of a 
C-6,7 double bond in the MA molecule, which 
prevents it from breakdown by the intestinal 
bacterial enzymes [22, 23]. A second advantage of 
MA is the ora,l way of application in contrast to 
MPA, which is routinely administered intra-
muscularly and thus may cause local irritation. 
Thirdly, the intramuscular administration of 
MPA leads to the formation of a depot which may 
interfere with the next kind of treatment at the 
time of progression [24-26]. 
The metabolic effects of MA observed in this 
study are similar to those reported for high-dose 
progesterone and MPA [27-34]. Our results are in 
agreement with a hypothesis in which the 
primary effect of MA would be an effect on 
hypothalamic-piwitary function resulting in 
decreased secretion of ACTH, LH, FSH and 
estradiol and increased secretion of prolactin. 
Animal experiments, however, were not un-
equivocal since administration of MPA or MA to 
rats bearing DMBA-induced mammary tumors 
[35] or estrogen-induced prolactinomas [36] 
caused a decrease in the circulating prolactin. 
Atrophy of pituitary adrenocorticotrophs after 
administration of progestins [35] is probably the 
explanation for the suppression of the pituitary-
adrenal axis,as found during long-term treatment 
with pharmacological doses of corticosteroids. 
The observed decrease in the plasma concentra-
tion of SHBG may be attribmed to the (anti-) 
androgenic properties of MA [37_. 38]. 
The observed increase in basal plasma insulin 
levels was not unexpected since progestins have 
been reponed to induce hyperinsulinaemia 
[39-42]. This is possibly a direct action on 
pancreatic islets [43], whereas an additional 
glucocorticoid-like effect on gluconeogenesis 
cannot be excluded. Progestins promote glycogen 
storage in the liver and stimulate deposition of 
body fat. Paradoxically, they antagonize the 
effects of insulin on glucose metabolism in 
adipose tissue and skeletal muscle [44-46]. The 
most relevant expression of these actions appears 
to reside in the physiology of normal pregnancy. 
Based on our observations, it is difficult to 
identify the increase of insulin as a primary or 
secondary effect. In conclusion, megestrol acetate 
induced multiple endocrine and metabolic 
changes, which could be attributed to the 
progestational, (anti-)androgenic and gluco-
corticoid proper_ties of the drug. None of these 
changes, nor the plasma concentration of MA, 
\Vere related to the clinical response. This may be 
explained by the occurrence of hormone-resistant 
tumor. Decrement of plasma estradiol may be 
important for hormone-dependent tumors, but 
we found no clear relationship between response 
of the tumors and the presence of the estrogen 
rceptors [5]. Also, estrogen-receptor-negative 
tumors can respond to MA. Besides an indirect 
effect, MA may have a direct cytotoxic effect 
because of glucoconicosteroid properties of the 
drug. On the other hand, high doses of progestins 
cause at least twice as many regressions as 
comparable doses of glucoconicoids (roughly, 35 
vs 15%). So a glucocorticoid-like ami-tumor effect 
cannot be the sole mechanism of action. On the 
basis of a relation with the androgen receptor [5, 
38], an extra anti-tumor effect may be attributed to 
the (anti-)androgenic effect of MA. 
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SUMMARY 
The progestin megestrol acetate and the anti-estrogen tamoxifen are used 
as effective and minimally harmful drugs in the treatment of metastatic 
breast cancer. The mechanism of action of either are not clearly 
understood, they may act directly on tumor cells, their receptors, or 
indirectly by changing the hormonal environment. The sequence and 
indications for use in practice still need to be defined. Of 21~ 
postmenopausal patients with metastatic breast cancer and measurable 
lesions, 136 were treated with megestrol acetate (liA) per os (180 mg daily) 
and followed by tamoxifen (TAH) (40 mg daily) in cases with progression, 
and 83 patients were treated with the inverse drug regimen. The interval 
between the treatment with these two drugs was less than 8 weeks, median 3 
weeks. In the first line treatment they showed similar effects: MA caused 
remission in 31/136 patients (23%) and TAH in 17/iJO patients (22%) (mean 
duration 12 and 13 months respectively), while as a second treatment line 
HA caused remission in 14/83 patients (!7%) and TAH in 12/!32 patients 
(9%), which was not significant (p=0.10). Also with respect to survival 
there was no significant difference between the two treatment modalities. 
When the groups were divided according to menopause (< 5 ; ~ 5 years) and 
age (< 60 ; ~ 60 years), significantly better results were obtained using 
the sequence HA/TAH in the less than 5 years postmenopause group, while in 
the 5 years or more pos tmenopause and younger than 60 years group the 
sequence TAM/HA was better. 
INTRODUCTION 
Anti-estrogens and synthetic progestins, widely used in the treatment of 
advanced breast cancer, both give a similar response rate of approximately 
30% in groups of patients, unselected as w biological and postmenopausal 83 
84 
age and receptor status, although the two drugs differ in chemical 
structure and in mechanism of action (Mouridsen and Palshof, 1978; 
Alexieva-Figusch, 1980, 1984). 
Since the early seventies, both kinds of drugs are used to replace the 
first line additive therapy with estrogens for late- and androgens for 
early-postmenopausal patients, which have several undesirable effects. A 
choice between anti-estrogens and progestins as first or second line 
treatment with regard to postmenopausal age and localisation of metastases 
has as yet not been established. 
Recently two randomized prospective studies were reported (Mattsson et 
al., 1982; Beretta et al., 1982) on the use of the progestin 
medroxyprogesterone acetate (MPA) versus tamoxifen (TAM) in the treatment 
of metastatic breast cancer, with the possibility of cross-over in case of 
tumor progression. In both studies MPA and TAM appeared to be equally 
effective as the first line treatment. Mattsson et al. (1982) reported a 
MPA induced response in 10/17 patients with tumors resistant to TAM, while 
only 2/13 patients with tumors resistant to MPA (intramuscularly) responsed 
to TAM. Beretta et al. (1982) reported equal response rates in second line 
with the sequence oral MPA/TAM (19%) and TAM/MPA (17%) in a not reported 
number of patients. On the other hand, not any patient resistant to 
intramuscular MPA responded to subsequent TAM. 
It should be mentioned that MPA administered intramuscularly leads to 
the formation of a depot (Camaggi, 1982) which may interfere with 
subsequent therapy if tumor progression occurs. For, when treating 
sequentially with these kinds of drugs, the antitumor effect of the second 
treatment may be influenced by changes in hormonal environment and receptor 
status caused by the first treatment and thus the effect of one drug could 
be potentiated or negated by the other. 
We have reviewed our own data on 219 postmenopausal 
metastatic breast cancer, treated sequentially with TAM 
patients with 
after MA vice 
versa, with the purpose of establishing which was the better sequence. 
MATERIALS AND METHODS 
From the postmenopausal patients with metastatic breast cancer treated 
in our clinic between 1975 and 1981 we evaluated all patients (219) with 
measurable progressive disease who had been sequentially treated with MA 
(180 mg daily orally) and then TAM (40 mg daily orally) or vice versa, with 
an interval between these two treatment regimens varying from 2 to 8 weeks. 
The treatment had been changed if the first therapy had appeared to be 
ineffective or if progression had occurred after a temporary response. The 
characteristics of the patients are shown in Table 1. 
Number of patients 
Median age (at diagnosis) 
Menopause ( 5 yrs 
> 5 yrs 
Median disease-free 
interval in months 
age < 60 yrs 
age > 60 yrs 
Localisation of metastases 
(dominant site) 
- Soft tissue 
- Bone 
- Viscera 
Previous hormonal therapy 
- Ovariectomy 
- Estrogen 
- Other 
Previous chemotherapy 
- CMF 
- Other (single drug) 
Table l 
Patient characteristics 
Megestrol 
acetate I Tamoxifen 
136 
62 
12 
38 
86 
12 
50 (37%) 
45 (33%) 
41 (30%) 
3 
9 
1 
4 
3 
Tamoxifen / 
Megestrol acetate 
83 
49 
50 
11 
22 
19 p=0.04 
27 (32%) 
32 (39%) 
24 (29%) 
37 
12 
2 
3 
2 
85 
One-hundred-thirty-six patients had been treated with MA followed by TAM 
(group A) and 83 patients with the inverse drug regimen (group B). Twenty 
patients in group A and 56 in group B had previously been treated with 
other ablative/additive hormonal- or chemotherapy. After cessation of 
previous estrogen therapy patients were not treated for a period of at 
least 8 weeks because of the possibility of a withdrawal regression. 
Patients with initial rapid progression during MA or TAM therapy as 
first line treatment, were treated with chemotherapy, and excluded from the 
study. 
According to the policy at that time, patients less than one year 
postmenopausal were treated by ovariectomy, and later at the time of 
progression with the anti-estrogen TAM. 
Thus, the 2 groups differ not only in age, but may be in hormonal 
sensitivity. This difference is also reflected by the fact that in the 
group of patients treated with ~~/TAM 10% (13/136) of the patients had been 
previously treated by hormonal therapy, whereas in the group TAI1/MA 61% 
(51/83), with disease-free interval 12 and 19 months respectively. 
The distribution of metastases was similar in both groups. The receptor 
status was known in only 22 patients and therefore not further considered. 
Before the start of treatment, a routine assessment of disease had been 
performed (physical examination, laboratory blood investigation, X-skeletal 
survey, bone- and liver scan, and fine needle biopsy of lymph-skin-liver 
metastases if necessary for diagnosis of metastatic disease. The results 
were assessed using the UlCC criteria for response (Hayward et al., 1977). 
The response was not evaluable in 3 patients treated with TAM initially 
and in 4 patients treated with MA subsequently. 
Statistics: 
The overall survival and remission data were analysed statistically 
using life tables and the logrank test (Peto et al., 1977). Wilcoxon's 
86 two-sample test was used to compare the effectiveness of the agents~ 
RESULTS 
The overall results are shown in Table 2. 
Table 2 Response to megestrol acetate and/or tamoxifen given as the lst and/or the 2nd line 
treatment in metastatic breast cancer 
Response 
C.R. 
P.R. 
N.CH. 
F. 
Overall 
response 
(CR,PR, 
N.CH) 
C.R. 
P.R. 
N.CH. 
F. 
Overall 
response 
(CR,PR, 
N.CH) 
1st Therapy 
Megestrol 
acetate 
8/136 
(23%) 
23/136 
73/136 (54%) 
32/136 (23%) 
104/136 
lst Therapy 
Tamoxifen 
6/80 
(22%) 
ll/80 
41/80 (51%) 
22/80 (28%) 
58/80 
CR complete remission 
PR partial 
N.CH no change 
F failure 
Median time to 
progression 
in months 
12 
7 
8 
13 
9 
9 
2nd Therapy 
Megestrol 
acetate 
6/83 
(17%) 
8/83 
38/83 (46%) 
31/83 (37%) 
52/83 
2nd Therapy 
Tamoxifen 
3/132 
(9%) 
9/132 
61/132 (46%) 
59/132 (45%) 
73/132 
Median time to 
progression 
in months 
9 
7 
8 
33 
6 
7 
87 
1) Megestrol acetate 
In the group of 136 patients treated with megestrol acetate before 
tamoxifen 31 patients (23%) showed an objective remission (CR+PR) with 
a median duration of 12 months, 73 patients (54%) showed no change 
(N.CH) with a median duration of 7 months, while 32 patients (23%) did 
not respond. 
2) Tamoxifen 
In the group of 80 patients treated with tamoxifen before megestrol 
acetate 17 patients (22%) showed an objective remission with a median 
duration of 13 months, 41 patients (51%) showed no change with a median 
duration of 9 months, while progression occurred in 22 patients (28%). 
1) Megestrol acetate 
In the group of 83 patients treated with megestrol acetate after 
tamoxifen 14 patients (17%) showed an objective remission with a 
median duration of 9 months, 38 patients (46%) showed no change with a 
median time to progression of 7 months, while 31 patients (37%) did 
not respond. 
2) Tamoxif en 
In the group of 132 patients treated with tamoxifen after megestrol 
acetate 12 patients (9%) showed an objective remission with a median 
duration of 33 months, 61 patients (46%) showed no change with a 
median time to progression of 6 months, while progression occurred in 
88 59 patients (45%). 
Megestrol acetate had a higher response rate as a first line agent than 
as a second line one (Wilcoxon's two sample test: p = 0.05). For tamoxifen 
(p < 0.01) this was equally true (Table 2). 
There was no significant difference between the percentage of patients 
in remission for 11 first line11 MA or TAM (Fig. lA) and "second line" MA or 
TAM (Fig. lB). Also there was no significant difference for overall 
remission (Fig. lC) and survival (Fig. lD) for both treatment modalities. 
A B 
'"'".' 
' ' 
c D 
- I N• 136) 1M/TAM 
ooo (N.83) TAM/MA 
The treatment modalities MA/TAM and Tfu~/MA in relation to 
A) Remission rate of 1st line MA or TAM 
B) Remission rate of 2nd line MA or TAM 
C) Overall remission of MA/TAM and TAM/MA 
D) Overall survival 
There was no significant difference. 89 
90 
However, in the group of patients treated with MA after TAM the response to 
the second line agent was better than the response to the first line agent 
in 15 out of 80 patients ( 19%) (Fig.2a), where<lS in the group of patients 
treated with TAM after MA the response to the second line agent '"as better 
than the response to the first line treatment in only ll out of 132 (8%) 
(Fig.2b). In this sense MA as second line agent was significantly better 
(p = 0.03) than TAM. 
Further, when either therapy sequence was considered in relation to the 
duration of the first and second response, the first response in the group 
MA/TAM (Fig.3a) was significantly longer than the second one (p = 0.02), 
while in the group TM1/MA there was the same tendency, but non-significant 
(Fig.3b). 
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a) 83 patients treated with the lst line tamoxifen (TAM) and 
their response to the 2nd line treatment with megestrol 
acetate (MA). Fifteen out of 80 patients (19%) responded 
~etter to the 2nd line (circled area). 
b) 136 patients treated with the lst line MA and their 
response to the 2nd line TAM. Better response to the 2nd 
line occurred in 11 out of 132 patients (8%). 
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Since the treatment groups differed with regard to age and years after 
menopause, a detailed analysis was done after subdivision into 
groups of patients: 
i) under 5 years postmenopause 
ii) over 5 years postmenopause aged under 60 years 
iii) over 5 years postmenopause aged 60 years or more 
(Table l) 
three 
In these subgroups disease-free interval and previous therapy did not 
appear to influence the response to TA1'1/MA or to t1A/TA1'1 treatment and 
equally not the time to progression on 2nd line treatment, measured from 
start of lst line, and were therefore not further considered. 
The following conclusions could be drawn from an extensive analysis 
(Figs.4A,B): 
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For the less than 5-year postmenopausal group of patients the best results 
were obtained with the sequence MA/TAM compared with the sequence TAM/MA: 
the percentage of failures in the first line was smaller with MA/TAM. 
The duration of response for the non-failures tended to be longer in the 
first line (n.s.) and the second line (p = 0.05) with MA/TAM in comparison 
with TAM/MA. 
Also the overall survival was longer (p 0 .02) in the MA/TA11 group 
(Fig.4A). Only the percentage of failures in the second line tended to be 
larger for MA/TAM than for TAM/MA. 
In the group of patients over 5 years after menopause, but younger than 
60 years, the sequence TA11/MA showed the best results: smaller percentage 
of failures in first and second lines, longer duration of response for the 
non-failures in the first line (p = 0.02) and a tendency for this in the 
second line (n.s.); further a longer survival (p = 0.001) (Fig.4B). 
For the group of patients aged 60 years or more no differences were 
found in response rate, duration of response or survival. 
Side effects 
------------
Serious side effects in either group were not numerous (Table 3). The 
most dangerous one, hypercalcemia, did not occur during the first line 
treatment, but did so in the second line treatment with TAM in 6 patients. 
Weight gain more than 2 kg was significantly higher during MA-therapy. 
Table 3 Side effects of megestrol acetate and tamoxifen 
1st line 2nd line 
MA TAM TAM MA 
Skin rash or itch 1 
Thrombophlebitis 3 
Lung embolism 
Hypertension 2 
Intolerance 4 3 
Hypercalcemia 6 
Weight gain > 2 kg 53 21 6 30 
Vaginal bleeding 93 
DISCUSSION 
From our results we may conclude that the overall results of the 
sequential treatments ~!A/TAM and TAM/~ are comparable with findings of 
Beretta et al. (1982), using oral MPA instead of~. 
In general, a bias in sequential studies may be the fact that some patients 
already need second line therapy before the first drug and metabolites are 
eliminated. For oral drugs such as we have used, the elimination time is 
shorter than for intramuscularly administered depot-ones. Plasma levels of 
MA, TAM, MPA given orally have fallen substantially 3 weeks after 
discontinuation of the treatment (which disappearance is dose dependent) 
whereas plasma levels after discontinuation of HPA i.m. remain unaltered 
for at least 6 weeks (Alexieva-Figusch et al., 1984; Fabian and Sternson, 
1982; Camaggi, 1982). 
Since the postmenopausal status and biologic age could influence 
responses to the treatment of metastatic breast cancer, the patient-
material was further statistically analysed in these directions in order to 
find indications for the choice between sequences ~/TAM or TAM/~. Our 
data showed that the sequence M.£1./TAM gave significantly better results in 
the group of patients under 5 years postmenopause (Fig.4A). This may 
suggest that, since tumor growth is generally more aggressive in early - as 
opposed to late - postmenopausal patients a hormonal agent with a broad 
spectrum of activity such as ~ might be more effective. For ~ has not 
only anti-estrogenic, but also androgenic and glucocorticoid properties 
(Alexieva-Figusch, 1984), and is effective in ER-negative patients 
(Teulings et al. 1980). 
We would like to emphasize again that the results of l1A and TM1 as first 
line treatment (response rates of 23 and 22%) may be lower as reported 
before (Alexieva-Figusch, 1980; Mouridsen, 1978), because of the selection 
of less favourable patients who needed second line treatment because of 
tumor prog,:-ession, in contrast to those patients who are still in long-term 
remission on 11 first line" treatment and therefore not considered in this 
94 study. 
CONCLUSION 
In conclusion: 
We are aware of the limitations of a retrospective study, which holds 
equally for prospective studies with small numbers of patients (Mattsson et 
al., 1982; Beretta et al., 1982). However, our analysed results lead us to 
propose tt1e following policy for choice between MA and TAM as a first line 
drug: :MA in patients less than 5 years postmenopause and TAM in patients 
over 5 years postmenopause and younger than 60 years. 
Randomized studies have to confirm the validity of these proposals. 
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ABSTRACT 
Six postmenopausal patients with metastatic breast cancer, who responded to 
megestrol acetate after 6 weeks of treatment, were treated with the combi-
nation of megestrol acetate and tamoxifen during the next 6 weeks. The study 
was oriented towards the endocrine effects of this combination, since it was 
known from our previous studies that megestrol acetate induces suppression 
of plasma gonadotropins and of the pituitary-adrenal axis, a decrease of 
peripheral concentration of SHBG and of estradiol, and an increase of basal 
and TRH-stimulated plasma prolactin concentration. Tamoxifen, on the other 
hand, produces a decrease of prolactin and gonadotropins, whilst estradiol 
remains unaffected. 
Although the role of prolactin in the growth of human breast cancer has 
not been elucidated yet and there is no unequivocal evidence that a decrease 
in plasma prolactin could be of benefit for treatment of metastatic breast 
cancer, we tested if addition of tamoxifen to the treatment regimen elimin-
ated megestrol acetate-induced hyperprolactinaemia. 
The results show that addition of tamoxifen to megestrol acetate treat-
ment annihilated the hyperresponse of prolactin to TRH stimulation, while 
basal prolactin levels remained unaffected. The negative effect on plasma 
gonadotropin concentration appeared to be amplified, while estradiol and 
cortisol were not affected, and SHBG increased. The results of these endo-
crine investigations merit a further study, directed to antitumor effects of 
this combination modality. 
INTRODUCTION 
Approximately 30% of patients with metastatic breast cancer will respond to 
a single agent endocrine therapy. The mechanism through which tumor re-
gression is achieved has not been completely resolved for any modality of 99 
endocrine treatment. Anti-estrogens are 
ference with the action of estrogens 
thought to act mainly by inter-
on estrogen-target cells [1,2]. 
Progestins on the other hand may act through their progestagenic- but also 
through glucocorticoid- and/or (anti-)androgenic properties [3]. Based on 
these differences in the presumed mechanism of action of anti-estrogens and 
progestins, an additional benefit might be expected from a combination of 
these two modalities. 
Iacobelli et al. [4] studied the interaction of the progestin medroxy-
progesterone acetate (MPA) and the anti-estrogen tamoxifen (TAM) on the 
growth of the human breast cancer cell line CG-5 (an estrogen-supersensitive 
variant of the MCF-7 cell line). They observed that addition of MPA and TAM 
together caused a stronger inhibition of cell growth than either agent 
alone. This potentiating effect might be achieved through steroid receptors. 
The biosynthesis of the progestin recep[or is known to be under estrogenic 
control. Antiestrogens deplete cytoplasmic estrogen receptor sites but also 
stimulate the synthesis of cytoplasmic progesterone receptors [5,6]. In 
addition, for the action of synthetic progestins with androgenic and gluco-
corticoid properties the presence of other than estrogen and progestin 
receptors could be important [7,8]. Alternatively, the potentiating effect 
of progestin and anti-estrogen treatment might be attributed to differences 
in their influences on the endocrine system. Both agents induce a decrease 
in the circulating concentrations of gonadotropins. Megestrol acetate (HA) 
induces a suppression of the pituitary-adrenal axis, a decrease in the 
circulating levels of sex-hormone-binding-globulin (SHBG) and estradiol and 
an increase in the plasma concentration of prolactin (PRL), both under basal 
conditions and after TRH stimulation [3]. Tamoxifen (TAM) has been reported 
to cause an increase of plasma SHBG and a decrease of PRL, while circulating 
estradiol levels remain unaffected in postmenopausal women [9,10,11]. 
Therefore, it may be expected that a combination of progestin and anti-
estrogenic drugs further suppresses the level of circulating gonadotropins, 
whereas the effects of progestins on SHBG and PRL are partly eliminated by 
antiestrogens. The present study was undertaken to evaluate this 
100 possibility. 
MATERIALS AND METHODS 
Seven patients with evaluable and measurable metastatic breast cancer, who 
were not yet treated otherwise for their metastatic disease, were selected 
for this study. All patients gave informed consent before participating in 
the study. They all were more than 4 years postmenopausal (two of them after 
adjuvant ovariectomy) and between 43 and 76 years of age. All patients were 
in good general condition, without gastrointestinal- hepatic- or renal 
disease, diabetes mellitus or malabsorption. Five patients had bone metasta-
ses and lung metastases were observed in 2 patients. None of the patients 
had soft tissue metastases only. The patients received a 6-week treatment 
with megestrol acetate (MA) 180 mg daily orally and after the clinical 
assessment of the response [12] only the 6 responders continued the treat-
ment with MA in combination with tamoxifen (TAM) 40 mg daily orally during 
the next period of 6 weeks. 
Routine clinical and biochemical investigations were performed at the start 
of the study, after 6 weeks of treatment with MA and after 6 weeks of treat-
ment with the combination of MA + TAM. In addition, blood was collected for 
the estimation of estradiol, SHBG, cortisol, LH and FSH. PRL and TSH were 
estimated before and after administration of 200 }lg TRH intravenously. PRL, 
TSH and estradiol were measured with commercial radioimmunoassay kits and 
SHBG by agar gel electrophoresis as described before [3]. Normal values: 
PRL: < 15 ng/ml TSH: <5 f1U/ml. Cortisol was measured by RIA, using the 
gammacoat kit from Clinical Assays (Cambridge, MA, USA); normal values at 
9.00 a.m. were ) 220 nmol/1. LH and FSH-levels were estimated using the Coat 
RIA solid phase radioimmunoassays from Biomerieux (Marcy l'Etoile, France). 
Results of these assays are expressed as ng/ml; 1 ng LH corresponds to 5 miU 
(MRC 68/40) and 1 ng FSH corresponds to 2. 7 mlU (MRC 78/579). The plasma 
level of tamoxifen was measured by thin-layer densitometry before and 6 
weeks after the addition of TAM to MA [13]. 
During the whole period of 12 weeks there was no change in other medications 
in order to avoid any influence on the endocrine parameters. 101 
102 
RESULTS 
The results obtained are summarized in Table 1 and indicate that the 
addition of tamoxifen to megestrol acetate annihilated the effects of MA on 
TRH-induced prolactin release and on SHBG. The effects of MA on basal PRL 
and cortisol levels appeared to be unaffected by addition of TAM, whereas 
the suppressive effect of MA on gonadotropins appeared to be amplified. 
Table 1 Effect of administration of megestrol acetate (MA) alone and in combination with 
tamoxifen (MA+TAM) on endocrine parameters in postmenopausal patients with 
metastatic breast cancer. 
(Results are given as means+ S.D., N=6) 
Parameter Before Treatment After 6 weeks MA 
Absolute % of pre Absolute % of pre 
treatment treatment 
value value 
* Basal PRL 6,6 .±. 3,5 100 
(ng/ml) 
10,0 ± 4,3 165 + 79 
* PRL 
(ng/ml) 
44,9 ± 16,7 100 66,9 ± 29,1 147 + 21 
(20' after. 
TRH) 
LH (ng/ml) 6,9 ±. 2,4 100 3,3 ±. 1,6 *I 49 + 26*1 
* * FSH 
(ng/m1) 
18,9 ±. 6,2 100 7,8±_4,7 41 + 20 
Estradiol 53 + 21 100 41 + 10 90 + 43 
( pmo1/ 1) 
* 
SHBG 19 + 14 100 14 + 16 66 + 15 
( nmo1/ l) 
* * Cortisol 431 + !59 100 97 + 141 19 + 26 
(nmo1/1) 
Tamoxifen N.D. 0 N.D. 
(nmo1/1) 
* 
p < 0,05 vs pretreatment value (Wilcoxon's test) 
** 
N.D. 
p < 0,05 vs value obtained after MA alone (Wilcoxon's test) 
not determined 
n = 4 
After 6 weeks MA 
+ 
6 weeks MA + TAM 
Absolute % of pre 
treatment 
value 
10,0 ~ 7,3 153 + 74 
** ** 40,3 ± 15,2 96 + 36 
* * 1,5 .±. 0,7 22 + 11 
* ** 3,4 ±. 1,8 19 + 8 
40 + 24 75 + 22 
** 23 + 15 141 + 99 
* 125 + 138 35 + 45 
** 610 + 125 N.D. 
Estradiol values were not affected by addition of TAM to MA. Because of a 
large heterogeneity observed in the magnitude of the parameters studied, the 
results were expressed not only in absolute values, but also as a percentage 
of the pretreatment values (Table 1). In addition, results of indivi:dual 
patients are shown in Figures 1 and 2. Sera, obtained after 6 weeks on MA 
treatment served as blanks for estimation of TAM serum levels, since it was 
not known whether MA or its metabolites are capable of interfering with the 
TAM assay. These blanks were essentially zero and thus the possibility of 
interference was ruled out. The combination was excellently tolerated 
without any signs of side-effects e.g. glucose tolerance deterioration, 
fluid retention or increase in blood pressure. 
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The concentration of prolactin in plasma before and after administration of 200 pg 
TRH in 6 breast cancer patients before, after 6 weeks on megestrol acetate therapy 
(MA) and after 6 weeks on the combination of megestrol acetate and tamoxifen (MA + 
TAM). 
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and 2. 103 
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Figure 2 The concentrations in the plasma of: 
a) LH, b) FSH, c) estradiol, d) SHBG and e) cortisol before, after 6 weeks on 
megestrol acetate therapy (MA) and after 6 weeks on combination of megestrol 
acetate and tamoxifen (MA + TAM) in 6 patients with metastatic breast cancer. 
Different symbols have consequently been used for the same patient in Figures 
and 2. 
DISCUSSION 
The present study confirms the results obtained in a previous series of 
breast cancer patients in which the endocrine effects of MA treatment were 
studied [3]. The hyperresponse of prolactin to TRH stimulation on HA 
treatment was eliminated by addition of TAM to MA, while basal PRL level 
tended to be lower in patients receiving the combination of both drugs 
(Table l, Fig.!). There is no equivocal evidence, however, that lowering of 
plasma PRL concentrations in itself is of benefit in the treatment of 
metastatic breast cancer. PRL could be involved, at least in a supportive 
role, in the development and growth of breast cancer, not only in animal 
models but also in humans [14,15]. Even though conflicting data exist about 
the involvement of prolactin in malignant breast tumor growth in humans, the 
presence of prolactin receptors in human breast tumors and the relation 
between prolactin and steroid hormone receptors indirectly supports an 
importance of this hormone as a growth factor in malignant neoplasia 
[ 16-20]. The inhibition of PRL secretion with the PRL-release inhibitor 
bromocriptine has recently been reported as a prophylaxis for spontaneous 
mammary tumorigenesis in rats [ 21] and of DHBA-induced mammary tumors in 
rats and mice [22]. TAM produced the same inhibition of tumor growth, while 
a further inhibition occurred when both TAM and bromocriptine were combined 
[23]. In human breast cancer bromocriptine as a single drug was ineffective 
[24] while after the addition of bromocriptine to medroxyprogesterone 
acetate a better response was suggested [ 25]. The influence of combination 
treatment of a steroid hormone and a prolactin inhibitor demands further 
investigation. 
A further lowering of gonadotropins elicited by TAM could have an 
additional inhibitory effect to that of MA. All 6 patients showed a decrease 
during MA therapy in plasma SHBG concentrations, while in only l of them no 
increase was observed after addition of TAM to the regimen. To assure that 
this could not be due to protocol violation or poor absorption, the serum 
levels of TAM were estimated. The patient whose SHBG did not increase after 
addition of TAM, had a plasma tamoxifen level comparable to that found in 105 
the other patients. The TAM levels observed (Table l) agree with those 
reported [13]. 
The glucocorticoid effect of MA seemed to be unaffected by addition of 
TAM. Cortisol levels remained very low in 4 patients; in 1 patient the 
suppression was very slow, and in 1 patient plasma cortisol recovered 
(Fig.2e). However, no data on MA levels were collected in this particular 
study and therefore a possible inadequately low level of MA, allowing an 
escape of suppression of the adrenal axis cannot be ruled out, 
Tumor response of this combination of drugs could not be considered in 
this study which was directed to the endocrine effects since only the 
responders to MA were treated with combination of both drugs. It can be 
mentioned, however, that all 6 patients are still in remission at the 
present moment (with a follow-up of 6-12 months). The fact that 6 out of 7 
patients (an extremely high "percentage" of ±. 85%), responded beneficially 
to MA simply demonstrates again that trials in small numbers of patients may 
be very useful for endocrine studies to indicate outlines for further 
research, but cannot be used for demonstration of the effectiveness ·of 
drugs. 
This combination treatment could become a new therapeutic approach and 
therefore a large study directed to its tumor effects has to be done. Also 
the possibility of dose reduction of both drugs, when given simultaneously, 
should be investigated. 
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GENERAL DISCUSSION, SUMMARY AND CONCLUSIONS 
In the course of time between the first publication on the subject, our 
experience, knowledge and sight has evolved, They have been incorporated in 
this discussion that is centered on the items of the introduction: 
1. How effective is megestrol acetate in the treatment of metastatic breast 
cancer? (Chapter II) 
Similar to what can be expected from any hormonal treatment, objective 
remissions ( CR+PR) were found in 30% of the patients with a median 
duration of 9 months. 
Some comments are useful, since the results of our study show the 
importance of defining relevant parameters for the evaluation of clinical 
trials to serve the final goal for doing them: to enable a choice for the 
best treatment modalities in individual patients. 
Our best results in the "dominant visceral" category which supposedly 
h ld b d 1 . c l ' 18 6 . h h s ou e worst un er 1nes ut ers op1nion t at t e category 
11 visceral" is too broad and should be assessed by the involvement of 
separate anatomical sites, e.g. lung and liver. It was also found that 
metastases in the lungs and pleura have a definite better prognosis 
during megestrol acetate administration than those in the liver. 
In addition to the data mentioned in Chapter II we tabelized the 
evaluation of these data in a comparative way (Table 1): 
Pleural and peritoneal metastases responded excellent to megestrol 
acetate administration, which could especially of benefit for those 
patients needing frequent aspirations of the effusions. This finding is 
in agreement with Panutti et al.'s (1981) 188 observations that 
medroxyprogesterone acetate concentrates nearly as highly in pleural and 109 
Table 1 MEGESTROL ACETATE THERAPY 
Dominant site compared to Anatomical site of metastases 
remission stable progr. remission stable progr. 
Viscera 11/:>5 [44% I 7/25 7/25 Viscera lung 5/18 [29%[ 8/18 5/18 
liver 0/ 7 I o%1 5/ 7 2/ 7 
muccous 8/14 [57%[ 1/14 5/14 
membr. 
other 5/20 [25%[ 10/20 5/20 
Bone 10/57 [18%[ 29/57 18/57 Bone 1/57 I 2%J 38/57 18/57 
Soft tissue 26/77 [34%[ 25/77 26/77 Soft tissue 40/111 [36%[ 40/111 31/111 
peritoneal effusions as in plasma. The very low response found in bone 
metastases (2%), could be explained by the mentioned heterogeneity of 
dominant site classification (Chapter I,8) and also by multiple bone 
involvement at the start of the therapy in many patients, in whom 
complete or partial remission could hardly be expected. On the other 
hand, a subjective improvement, such as diminishing of pain, improving of 
validity, sense of being well, occurred frequently, but they are not 
expressed in figures that concern objective evaluation, how important 
they may be for the patients. 
2. What is the role of steroid receptors in the mechanism of action of 
megestrol acetate in tumor regression ? (Chapter III and IV) 
By virtue of the capability of steroid receptors to bind steroids and 
thereby facilitate the transport of the steroid-receptor complex to the 
intracellular site of action, steroid receptors have been implemented in 
the mechanism of action of additive steroid therapy in breast cancer 
(Chapter I,3). The way in which the antitumor effect is reached, is not 
exactly understood yet. 
When patients were selected, with regard to ER status, for the treatment 
with estrogens, androgens or glucocorticoids, objective responses were 
110 found in+ 60% of patients with ER+ tumors while an additional improve-
68 77 
ment was found if also PgR was present. ' 
patients with ER+ tumors did not respond. 
On the other hand, some 
Also, other mechanisms of action could be involved such as a direct 
cytotoxic effect of pharmacological dosages of steroid hormones and 
activation or inhibition of enzymes. 
Tumor response during MA treatment showed no clear correlation with the 
ER content. However, the duration of remission of patients with ER+ 
tumors was significantly longer ( p < 0.01) than in those whose tumors 
lacked the estrogen receptor. Also the suggestion that progestins would 
act on the breast cancer cell by means of the progesterone/estrogen 
receptor mechanism and subsequent increase of 17~ dehydrogenase activity 
113 (E 2DH) could not be confirmed in our study. However, Satyaswaroop et 189 
al. warned that the ineffectiveness of progestins to induce E
2
DH in 
endometrial cancer specimens in vitro is related to instability of PgR 
under culture conditions. Also, it is possible that for the appearance of 
specific PgR estrogen-priming is necessary. 
Megestrol acetate and medroxyprogesterone acetate are strong competitors 
for steroids which bind specially to androgen, glucocorticoid and 
progesterone receptors, indicating that the progestins are able to bind 
to these receptors with high affinity. As mentioned before (Chapter 1,2), 
the chemical structure of individual progestins provides androgenic or 
glucocorticoid activity and the binding to other receptors such as 
androgen and glucocorticoid might be expected. 
The observed tumor regressions were significantly associated indeed, with 
the presence of large amounts of androgen receptors in the tumors, while 
correlations with the glucocorticoid receptor, (p=0.07), with the 
estrogen (p=0.34) and the progestin receptors (p=0.24) were not signifi-
cant. On the other hand, with increasing amount of ER there was also an 
increasing amount of the other receptors. 
It is not possible nor feasible to estimate ER, PgR, AR and GR in tumor 
specimens of all patients. However, the presence of high contents of ER 
predicts the simultaneous presence of other receptors, increasing chance 
to a beneficial response to any hormonal treatment. 1 i 1 
3. Has the effect of megestrol acetate on some endocrine parameters any 
relation to tumor regression? What is the optimal dose? (Chapter V) 
The effect of MA on some endocrine parameters is most intervential. MA 
may centrally inhibit hypothalamic-pituitary functions resulting in a 
decreased secretion of LH, FSH, ACTH and an increased secretion of 
prolactin. This finally results in a decrease of plasma estradiol and 
cortisol concentrations. 
An increase of the basal plasma insulin level could be attributed to the 
action of progesterone, in the case of progestins, however, also to their 
additional glucocorticoid-like effects (Chapter I,S). 
In our study these endocrine events were found in all patients in a 
dose-dependent way, in responders and non-responders equally. It seems 
likely that these metabolic events are non-specific. On the other hand, 
blood levels of circulating hormones do not per se reflect the hormonal 
situation around the tumor. The patients of the present study were not 
pre-selected for hormonal treatment by presence of a receptor. Further 
investigations, in patients with known ER, PgR, AR and GR contents in 
tumor specimens may elucidate, whether these endocrine effects mentioned 
might have influenced tumor growth. It should be kept in mind that each 
additive endocrine therapy usually exceeds physiological hormone levels 
by far and consequently may produce a direct cytotoxic effect on both 
normal and tumor cells in addition to endocrine and metabolic changes. 
It was the purpose of our study to find an optimal effect using the 
minimal dose of the drug to avoid the adverse effects. From the three 
dosages of MA used, the 180 mg dose seems to fulfil these aims. 
4. In what sequence should hormonal treatment with megestrol acetate be 
used ? (Chapter VI) 
From our retrospective study no clear answer could be given. The compared 
groups differ markedly with respect to median age, previous therapy such 
112 as ovariectomy and disease-free interval. The overall results, the 
response rates and their duration and survival did not differ when using 
the sequence MA/TAM or TAM/MA. 
Theoretically, if the action of both drugs on the receptors is taken into 
account, the sequence of TAM/MA should give favourable responses due to 
deplenishment of ER and replenishment of PgR by TAM to create an optimal 
situation for progestin action. 
It should be considered, that the receptor status is changing190 in 
patients on long-term treatment and therefore this phenomenon could be 
used in an alternating treatment regimen, which will be the matter of our 
future investigations. 
5. Does the combination of megestrol acetate and tamoxifen have an ad-
ditional effect on endocrine events; especially can the MA-induced 
hyperprolactinaemia be suppressed by the administration of tamoxifen ? 
(Chapter VII) 
Treatment with this combination exerted an additional effect by lowering 
the circulating gonadotropins levels further than by MA alone. The 
elevated basal plasma PRL concentration remained unaffected by addition 
of TAM, while the hyperresponse of PRL to TRH became normalized. It needs 
to be established whether the lowering of PRL itself could be of 
importance as a primary goal for the treatment of metastatic breast 
cancer. Since this combination might become a new treatment approach it 
will be a matter of a next large study, directed not only to tumor 
response, but also to the possibility of dose reduction and diminishing 
of adverse effects. 
113 
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CONCLUSIONS 
1. Megestrol acetate is effective in the treatment of metastatic breast 
cancer; response rate and its duration is similar as could be expected 
from any hormonal treatment; serious side effects are negligible. 
2. No clear correlation between clinical response to treatment with MA and 
ER and PgR has been found; for MA, it seems that only the androgen 
receptor may be useful as a marker for response to this therapy. All 
tumors high in androgen receptor were also ER+. 
3. Megestrol acetate caused (dose dependently) an increase of the basal and 
TRH-stimulated plasma PRL levels and of basal insulin concentrations, 
whereas LH and FSH, estradiol, SHBG and the pituitary-adrenal axis were 
suppressed. The dose of 180 mg seems to be optimal. None of these 
metabolic effect showed a correlation with the clinical response. 
4. Megestrol acetate is effective as the first as well as the second line in 
additive hormonal treatment. 
5. The combination of megestrol + tamoxifen exerts an additional effect by 
further lowering the circulating gonadotropins levels and normalized the 
hyperresponse of PRL to TRH stimulation. 
SAME NV ATTING 
In dit proefschrift wordt besproken de rol van het synthetische 
progestageen megestrolacetaat in de behandeling van gemetastaseerd 
borstkanker. Nadat het resultaat op het tumorproces vastgesteld was, kwamen 
vragen op omtrent het werkingsmechanisme, de optimalE plasma concentratie, 
de invloed op endocriene en metabole functies, ongewenste bijwerkingen, 
indicaties voor deze therapie, en over eventuele verbetering van het 
therapeutisch effect door combineren met een ander geneesmiddel. 
In hoofdstuk I zijn de historische aspecten behandeld. Ondanks de 
ontdekking van progesteron al in de dertiger jaren was het gebruik van dit 
hormoon in de behandeling van borstkanker naast andere hormonale therapie 
beperkt door de korte biologische beschikbaarheid na orale toediening. Dit 
probleem werd opgelost toen in de zestiger jaren synthetische progestagenen 
met langere levensduur ter beschikking waren gekomen. Deze stoffen waren 
niet alleen aktiever dan progesteron, maar waren ook werkzaam bij orale 
toediening. 
Voor veel fysiologische werkingen van progesteron is een "priming" met 
oestrogenen noodzakelijk. Terwijl oestrogenen de groei stimuleren, bevordert 
progesteron in het algemeen de rijping en differentiatie van de cellen. 
Synthetische progestagenen kunnen op basis van de chemische structuur 
meerdere eigenschappen hebben, o.a. androgene, anti-androgene en 
glucocorticoide werkingen. 
De plasmaspiegel van megestrolacetaat, gemeten na 60 mg orale do sis 
bereikte een maximum na 1-4 uur (43 ng/ml), was nog meetbaar na 24 uur (9,6 
- 26 ng/ml) en nog aanwezig in zeer lage concentratie (0,7 - 3 ng/ml) na 7 
dagen. De biologische halveringstijd van deze dosis was 3! dag. 
Ret is de veronderstelling, dat een steroid hormoon zijn functie in de 
eel pas kan uitoefenen als een daarvoor specifieke receptor aanwezig is in 
het cytoplasma. Tumor regressie na therapie met progestativa zou mogelijk 115 
gezien moeten worden in relatie tot het endocriene milieu om de kankercellen 
heen en de therapie zou voornamelijk gericht moeten worden op interferentie 
met een van oestrogenen afhankelijk groeiproces. Hormonale manipulatie zou 
kunnen interfereren met de synthese en turnover van de oestrogeen receptor 
en ook met die van andere receptoren. 
Verdere mogelijkheden zijn een directe cytotoxiciteit van hoge 
concentrat.:i.es van een hormoon of een indirekte invloed op het hormonale 
milieu, zoal:~ daling van plasma concentraties van LH, FSH, oestrogenen, 
androgenen, co tisol en ACTH en stijging van prolactine. 
In hoofdstuk II werd in een klinische studie van 160 patienten het 
effect van megestrolacetaat op gemetastaseerd mammacarcinoom beschreven. De 
resultaten zijn beoordeeld volgens algemeen geaccepteerde UICC criteria. 
Remissie trad op in 30%, stabilisatie van de ziekte in 36% terwijl 34% van 
de patienten niet reageerden op de therapie. De remissies duurden gemiddeld 
9 maanden. 
De postmenopauzale status is een belangrijke prognostische faktor bij 
mammacarcinoom. Bij de verdeling van de hele groep naar een postmenopauzale 
status minder dan 5 en meer dan of gelijk aan 5 jaar bleek dat de groep van 
patienten meer dan of gelijk aan 5 jaar postmenopauze een significant beter 
resultaat had. 
In hoofdstuk 1 - 8 en discussie is dieper ingegaan op de problemen met 
de juiste beoordeling van de resultaten. De indeling naar "dominant sites of 
metastases 11 is gebaseerd op een aantal studies, waaruit bleek dat patienten 
met viscerale metastasen de slechtste prognose hadden wat betreft 
overleving. 
In onze studie hebben wij tegen de op deze verdeling gebaseerde 
verwachting een zeer goed resultaat gevonden bij viscerale metastasen. Deze 
bevindingen komen overeen met de opvatting van andere onderzoekers dat de 
begrippen "dominant" en "visceral sites" misleidend kunnen zijn en dat het 
classificeren van resultaten van therapie bij gemetastaseerd mammacarcinoom 
116 tevens naar gespecificeerde localisaties dient te gebeuren. 
In hoofdstuk III en IV, werd het werkingsmechanisme van 
megestrolacetaat besproken. Er is geen duidelijke correlatie gevonden tussen 
de aanwezigheid van oestrogeenreceptoren en de reactie van de metastasen, 
echter, de duur van de remissie bij de patienten met ER+ tumoren was 
significant langer (p < 0,01) dan bij ER- tumoren. 
De veronderstelling dat de activiteit van het enzym 17p-dehydrogenase 
verhoogd zou zijn als bewijs van betrokkenheid van de progestageenreceptor 
in het werkingsmechanisme kon in onze studie niet worden bevestigd. 
Aan de andere kant is er een significante correlatie gevonden tussen 
het optreden van tumor respons en de gevonden hoeveelheid van androgeen-
receptor en een net niet significante correlatie met die van glucocorticoid-
receptor. 
Gezien de androgene- en glucocorticoide eigenschappen van megestrol-
acetaat was deze gevonden correlatie te verwachten. 
In hoofdstuk V, werd de invloed van behandeling met megestrolacetaat op 
sommige endocriene parameters besproken evenals de relatie met de gegeven 
dosis. 
Megestrolacetaat remt de functie van het hypothalamus-hypofyse-systeem 
hetgeen zich uit in een verminderde secretie van LH, FSH, ACTH en verhoogde 
secretie van prolactine met een daling in de concentratie van oestradiol en 
cortisol. De gevonden verhoogde plasma insulinespiegel, kunnen toegeschreven 
worden aan de progesteronachtige werking, waaraan de glucocorticoide werking 
van megestrolacetaat een additioneel effect geeft. 
Al deze endocriene veranderingen werden gevonden bij alle patienten; 
het effect was dosis-afhankelijk bij responders zowel als bij 
non-responders. Ret leek dus waarschijnlijk dat al deze effecten niet 
specifiek van invloed waren op de reactie van de tumor. Bovendien hoeft de 
plasmaspiegel van hormonen geen informatie te geven over de concentratie van 
deze hormonen in de (naaste omgeving van de) tumor. 
Hoofdstuk VI behandelt de plaats van megestrolacetaat in de hormonale 
therapie bij mammacarcinoom. Er is een vergelijking gemaakt tussen de 
volgorde antioestrogeen gevolgd door megestrolacetaat en omgekeerd. De 117 
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resultaten van de ene en de andere volgorde waren hetzelfde wat betreft 
percentage- en duur van remissie en van overleving. 
In hoofdstuk VII werd nagegaan of een combinatie van megestrol-
acetaat met tamoxifen nog een additioneel effect kan hebben op de endocriene 
parameters, met name normalisatie van door de megestrolacetaat geinduceerde 
hyperprolactinaemie. 
Door deze combinatie werd een nog diepere daling van gonadotropinen 
bereikt. De verhoogde basale plasma prolactine concentratie werd niet 
beinvloed door de bovengenoemde combinatie, terwijl de hyperreactie van door 
TRH gestimuleerde prolactine wel geelimineerd werd. 
Het is nog niet duidelijk of verlaging van de plasma prolactine 
concentratie een belangrijke factor is voor de succesvolle behandeling van 
gemetastaseerde borstkanker. 
Deze beperkte endocriene studie moet in de toekomst uitgebreid worden 
om de invloed van deze combinatietherapie op de tumorgroei en regressie vast 
te leggen. 
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